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INTRODUCTION
Nephrotic  Syndrome is  a  common glomerular disorder affecting children.  It  is 
characterized by heavy proteinuria, hypoalbuminemia, edema and hypercholesterolemia. 
The incidence is 2-3 per 1, 00,000 children per year (1).
Approximately 90% of children with Nephrotic Syndrome have some form Idiopathic 
Nephrotic Syndrome. This includes 3 histological types:
• Minimal Change Disease
• Mesangial Proliferative Glomerulonephritis ( MesPGN) 
• Focal Segmental Glomerulosclerosis
Corticosteroids  like  Prednisolone  are  the  recommended first  line  treatment  for 
nephrotic  syndrome.  Majority  of  children  have  Steroid  Sensitive  Minimal  Change 
Disease. Most children with Steroid Sensitive Nephrotic Syndrome (SSNS) have repeated 
relapses, which generally decrease in frequency as the child grows older (1).
Glucocorticoids are used in myriad other pediatric diseases. It is estimated that 
10%  of  children  may  require  some  form  of  glucocorticoids  at  some  point  in  their 
childhood (2).  Prolonged steroid use is  known to cause osteoporosis.  Decreased bone 
mineral  density (BMD) has  been described  in  various  pediatric  disorders  that  require 
glucocorticoids,  including  asthma,  juvenile  rheumatoid  arthritis,  inflammatory  bowel 
disease,  systemic lupus erythematosus,  and organ transplantation (3-6). Impairment of 
childhood  growth  with  an  approximate  cortisone  dose  of  1.5  mg/kg/day  was  first 
described over 40 years ago; osteopenia in children receiving a Prednisolone dose of less 
than 0.16 mg/kg/day has also been reported (7, 8).
37,000  children  were  studied  in  UK  by  Van  Staa  et  al  (9),  to  evaluate  the 
incidence of fractures among pediatric glucocorticoid users .Results showed that the risk 
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of  fracture  was  increased  in  children  who  received  four  or  more  courses  of  oral 
corticosteroids for a mean duration of 6.4 days. Fracture risk was also increased among 
children using 30 mg Prednisolone or more each day.
Childhood  Steroid  sensitive  nephrotic  syndrome  provides a  clinical  model  of 
chronic glucocorticoid therapy in the absence of significant underlying disease activity. 
The  course  of  SSNS is  characterized  by relapses  which result in  protracted,  repeated 
courses of  glucocorticoids. The standard Prednisolone  dose for new onset disease and 
relapses is 2 mg/kg per day which far exceeds the 5 mg/day that is considered a risk factor 
for Glucocorticoid induced osteoporosis in adults (3).
While  osteoporosis  has  long  been  considered  a  disease  of  the  aging,  there  is 
increasing awareness that children are not exempt from developing the disease. Threats to 
bone health that are operative during the pediatric years may be particularly costly long-
term,  since  growth  and  development  of  the  skeletal  system  play  a  critical  role  in 
determining bone strength and stability in later years (10).
Although the deteriorative effect of steroid treatment on children’s bones  
has been well known for years, no recommendations have been suggested for the 
prevention of diminished BMD and BMC in children with nephrotic syndrome. 
There are no clear cut guidelines as to when bone protective strategies must be  
instituted. This study was thus undertaken to determine the protective efficacy of  
Calcium and Vitamin D supplementation in children with Nephrotic Syndrome on  
short  term  steroids.  Using  Bone  Mineral  Density  (BMD)  and  Bone  Mineral  
Content (BMC) as tools, those receiving supplementation were compared with  
those not receiving it. 
The results will enable us to draw protocols / guidelines for institution of bone 
protective therapy for children on short term steroids.
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AIM
To study the effect of short term corticosteroid therapy and the prophylactic role 
of Calcium and Vitamin D on bone health in children with nephrotic syndrome
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OBJECTIVES
PRIMARY OBJECTIVES
• To study the  effect  of  short  term steroids  on  bone  in  children  with  nephrotic 
syndrome using serial measurements of Bone Mineral Density (BMD) & Bone 
Mineral Content (BMC)at the Lumbar spine.
• To evaluate the role of prophylactic Calcium and Vitamin D in preventing short 
term steroid induced bone loss in children with new onset Nephrotic Syndrome
SECONDARY OBJECTIVE
• To study the adverse effects of steroid therapy
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LITERATURE REVIEW
NEPHROTIC SYNDROME
Childhood Nephrotic syndrome is a chronic glomerular disorder.  It is a disorder 
of glomerular capillary wall permeability that may be primary, or secondary to an overt 
systemic disease.
Nephrotic  syndrome  is  characterized  by  heavy  proteinuria,  hypoalbuminemia 
(<2.5 g/dl), edema & hypercholesterolemia (>200 mg %) (1). Proteinuria is considered to 
be in the nephrotic range when the urine protein is  3+/4+ on a dipstick ,  Spot Urine 
Protein / Creatinine ratio is > 2 or Urine Albumin > 40 mg / m2/ hour  (on a timed 
sample) (11). 
The  International  Study of  Kidney Disease  in  Children  (ISKDC)  reported  the 
following distribution by histology in children with nephrotic syndrome (12):
Glomerular Histology %  distribution
Minimal Change Disease  ( MCD) 77 %
Focal Segmental Glomerulo Sclerosis  (FSGS) 10 %
Proliferative Glomerulonephritis
Membranoproliferative  (MPGN) 5 %
Diffuse Mesangial  (DMP) 3 %
Crescentic  (CGN) 3 %
Membranous Nephropathy  ( MN) 2 %
Idiopathic nephrotic syndrome is the most common form of nephrotic syndrome in 
children,  representing  more  than  90  percent  of  cases  before  10  years  of  age  and  50 
percent  after  10 years  of  age (13).  Idiopathic  nephrotic  syndrome is  characterized by 
diffuse  foot  process  effacement  on electron  microscopy and Minimal  changes  (called 
minimal  change  disease  (MCD),  Focal  segmental  Glomerulosclerosis  (FSGS),  or 
Mesangial proliferation on light microscopy.
Patients  with histological  findings  of  MCD are generally responsive to steroid 
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therapy.  Because clinical  findings are  highly predictable in  differentiating MCD from 
other forms of nephrotic syndrome, steroid therapy is initiated in patients who are likely 
to  have  MCD based  upon clinical  criteria  without  histological  confirmation  by renal 
biopsy. One third of patients with FSGS will also initially respond to steroid therapy.
Clinical experience has demonstrated that the response to steroid therapy rather 
than  the  histological  features  seen  on  renal  biopsy  is  better  at  predicting  long-term 
prognosis. Patients with nephrotic syndrome can be defined by their response to steroid 
therapy as follows:
Steroid-sensitive nephrotic syndrome - More than 90 percent of patients who respond 
to steroid therapy have MCD, and FSGS is seen in the remaining patients (14). Steroid 
sensitive NS is considered to be a relatively benign condition; progression to end stage 
renal  failure  is  extremely rare  and over  80 % achieve spontaneous remission in  later 
childhood.
Steroid-resistant nephrotic syndrome - One-fourth of the patients who fail to respond 
to steroids have MCD (14). Patients who fail an initial course of steroids should undergo 
renal biopsy to determine the underlying diagnosis to guide further therapeutic choices.
Some of the terms that help define the course of the disease are as follows:
REMISSION: Urine  Albumin  nil  or  trace  (or  proteinuria  <  40  mg /  m2  /  h)  for  3 
consecutive days
RELAPSE: Urine Albumin 3+ or 4+ (or Proteinuria > 40 mg/m2/hr) for 3 consecutive 
days, having been in remission previously
FREQUENT RELAPSES: 2 or more relapses in 6 months of initial response, or more 
than 3 relapses in any 12 months.
STEROID  DEPENDENCE:  Occurrence  of  2  consecutive  relapses  during  steroid 
therapy or within 2 weeks of cessation.
STEROID  RESISTANCE:  Absence  of  remission  despite  therapy  with  daily 
prednisolone in a dose of 2 mg/ kg /day for 8 weeks.
The aim of  management  of  Nephrotic  Syndrome in  children  is  to  induce  and 
maintain  remission  with  complete  resolution  of  proteinuria  and  edema  without 
encountering serious adverse effects of therapy.
STEROID THERAPY
Empiric  steroid therapy can be initiated in patients with a  high probability of having minimal 
change (MCD) without confirmation of the diagnosis by renal biopsy because more than 90 percent of 
patients with MCD will respond to corticosteroid therapy within eight weeks (14, 15). Initial steroid therapy 
is given to patients who fulfill all of the following criteria. 
• Age older than 1 year and younger than 10 years of age 
• None  of  the  following  findings:  hypertension,  gross  hematuria  and  a  marked 
elevation in serum creatinine 
• Normal complement levels 
• No extra-renal symptoms such as malar rash or purpura 
Idiopathic nephrosis is steroid-responsive in most children (14). Approximately 30 
percent of treated patients will not have a relapse and are therefore cured after the initial 
course  of  therapy  (15).  Ten  to  20  percent  will  relapse  several  months  after  steroid 
treatment is discontinued, but will have less than four steroid-responsive episodes before 
permanent remission occurs. However, 30 to 40 percent of patients will have frequent 
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relapses, and some patients will relapse while on steroid therapy.
Patients who are frequent relapsers or steroid dependent often require multiple 
and/or prolonged courses of steroid therapy and are at risk for steroid toxicity. A longer 
duration of the initial course of steroids, which includes periods of daily and alternate day 
steroids,  appears  to  reduce  the  risk  of  relapse  and  decreases  the  cumulative  dose  of 
steroids (16-19).
This is illustrated by a meta-analysis that included 12 trials (17). The following findings 
were noted:
• In  a  pooled  analysis  from six  trials,  treatment  with  Prednisolone  for  three  to 
seven months reduced the risk of relapse at 12 to 24 months post-therapy versus 
that observed with a two-month regimen (RR of 0.70 95% CI 0.58 to 0.84). There 
was no difference in cumulative steroid dose. 
• In a pooled analysis of four trials of 382 children, the risk of relapse was lower 
with six versus three months of therapy (RR of 0.57, 95% CI 0.45 to 0.71). There 
was no difference in cumulative steroid dose.
• A reduced risk of relapse was associated with both an increase in the duration and 
an increase in the dose of steroid therapy. 
Similar  findings  were  seen  in  a  randomized  controlled  trial  from  the 
Arbeitsgemeinshaft für Pädiatrische Nephrologie (APN) that compared a standard initial 
treatment of Prednisolone 60 mg/m2 per day for four weeks, to a longer initial regimen of 
six weeks of continuous prednisone 60 mg/m2 followed by six weeks of alternate day 
prednisone  of  40  mg/m2  (18).  The  subsequent  relapse  rate  within  12  months  after 
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discontinuation of continuous therapy was lower with the prolonged course of therapy 
compared to the standard treatment (36 versus 61 percent).
Increasing initial immunosuppression by adding Cyclosporine to steroid therapy 
had  been  proposed  as  a  way  to  reduce  the  relapse  rate.  However,  the  addition  of 
cyclosporine does not alter the two-year relapse rate and the combination of cyclosporine 
and Prednisone compared to prednisone alone results in a greater number of side effects 
(20, 21). As a result, steroids alone are used as the initial therapy for childhood nephrotic 
syndrome.
Time to response 
In a report from the International Society of Kidney Disease in Children (ISKDC), 
approximately 90 percent of patients who will respond to steroids do so within four weeks 
after starting steroids, with the remaining 10 percent going into remission after two to 
four more weeks of a daily steroid therapy (12).
Options in those who are not in remission after four weeks of daily steroid therapy 
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include the following:
• 3 pulses of Methyl Prednisolone (1000mg/1.73 m2) on alternate days.  Patients 
who have persistence of proteinuria one week after this treatment are considered 
steroid resistant and a renal biopsy is performed.
• Biopsy patients without administering the three pulses of Methyl Prednisolone, as 
there is an increased likelihood that they have another glomerular disease that may 
not be responsive to additional steroid therapy. 
• Continue daily steroid therapy for another four weeks because an additional 10 
percent of steroid responsive patients  will  respond after  four weeks of therapy 
(12). 
Patients who fail to respond to a maximum eight weeks of daily steroid therapy are 
considered steroid resistant and require a renal biopsy to determine the underlying 
glomerular disease (12). 
Outcome based upon steroid response 
• A report from the ISKDC evaluated the outcome of 389 children with minimal 
change disease  who were  followed  for  a  mean  of  9.4  years  based  upon their 
response to initial steroid therapy (13). Following results were noted:
• Ninety-two  percent  of  patients  responded  to  steroids.  Of  this  group  of  334 
patients, 41 percent did not relapse within six months after the initial course of 
steroid therapy, 28 percent relapsed frequently, 20 percent had a single relapse 
within the six month time period, and 3 percent failed to respond to subsequent 
courses of steroid therapy. 
• Prognosis was best in the steroid-responsive patients who did not relapse in the 
first six months. Approximately 75 percent either continued in remission during 
follow-up or relapsed rarely. Only 4 percent became frequent relapsers. 
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• Patients with persistent proteinuria after eight weeks of steroid therapy (steroid-
resistant) had a 21 percent risk of progression to end-stage renal disease (ESRD). 
This  risk  rose  to  35  percent  among  the  60  percent  of  initial  steroid-resistant 
patients  who  had  persistent  proteinuria  six  months  after  the  initial  course  of 
steroid therapy.
• Overall, 95 percent of children did well, 4 to 5 percent died from complications 
(eg, peritonitis) or progressed to ESRD. 
EFFECTS OF CORTICOSERROIDS
Glucocorticoids are important regulators of diverse physiological systems and are 
often used in the treatment of a number of renal, chronic inflammatory, autoimmune, and 
neoplastic  diseases.  It  is  estimated that  10%  of  children  may  require  some  form of 
corticosteroids at some point in their childhood (2).
At  physiological  levels,  glucocorcorticoids  are  involved  in  negative  feedback 
modulation  of  corticotrophin  releasing  factor  and  Adrenocorticotropic  hormone, 
maintenance of blood glucose and liver glycogen levels, maintenance of cardiovascular 
function,  blood  pressure  and  muscle  work  capacity,  excretion  of  a  water  load  and 
protection against moderate stress. They are unique among pharmacological agents in that 
being synthetic analogues of chemicals produced by the body they have physiological and 
pharmacological activities.
Two categories  of  adverse  effects  occur  with  the  therapeutic  use  of  systemic 
glucocorticoids: those resulting from prolonged use of large doses and those resulting 
from withdrawal of therapy.
The adverse effects of Glucocorticoids include:
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1. Effects on Bone
 a. Osteopenia / Osteoporosis 
 b. Avascular Necrosis
 
Infancy  and  childhood  are  important  periods  of  life  for  bone  development. 
Prolonged steroid use is known to cause osteoporosis. Impairment of childhood growth 
with an approximate cortisone dose of 1.5 mg/kg/day was first described over 40 years 
ago; Osteopenia in children receiving a prednisolone dose of less than 0.16 mg/kg/day has 
also been reported (7, 8).
Loss of bone and deterioration in short term growth are dependent on the type and 
dose of glucocorticoids. Moderate to high dose glucocorticoid therapy is associated with 
loss of bone and increased risk of fracture (22).
Studies have shown that the greatest reduction in bone mineral content (BMC) and 
BMD  among  children  with  leukemia  occurred  during  the  first  6–8  months  of 
chemotherapy (23 – 26), similar to the potent Glucocorticoid effect on bone seen in the 
adult  population.  The  temporal  pattern  of  bone  mass  changes  in  adults  with 
Glucocorticoid-induced  osteoporosis  appears  to  be  biphasic,  with  a  precipitous  drop 
observed in the first 6–12 months of therapy, followed by a gradual, but sustained, loss in 
subsequent years (27, 28).
GCs  toxicity  appears  to  have  a  predilection  for  trabecular  bone,  which  has  a 
higher  metabolic  activity  than  cortical  bone,  and  thus  may be  more  sensitive  to  the 
deleterious effect of steroids (29). This is supported by the propensity of GCs to affect the 
spine.
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The mechanisms by which steroids affect bone are many:-
Glucocorticoids  have  a  suppressive  effect  on  osteoblastogenesis  in  the  bone 
marrow  and  promote  the  apoptosis  of  osteoblasts  and  osteocytes,  thus  leading  to 
decreased bone formation (30). Accumulation of apoptotic osteocytes may also explain 
the so called "osteonecrosis", also known as aseptic or avascular necrosis. There is some 
evidence to suggest that Glucocorticoids may also increase bone resorption by extending 
the lifespan of pre-existing osteoclasts (31). 
Glucocorticoids may also promote calcium loss through the kidney and gut, and 
this  negative  calcium  balance  can  itself  lead  to  increased  bone  remodeling  and 
osteoclastic activity due to secondary hyperparathyroidism (32). 
Glucocorticoids  may also  impair  the  attainment  of  peak  bone  mass  and delay 
growth through alterations in gonadal function at the level of the pituitary and through 
direct effects on the gonads. Studies in adults show that glucocorticoid therapy may be 
associated with testosterone deficiency as well  as reversible gonadotrophin deficiency 
(33, 34). Levels of other sex steroids such as androstenedione and estrogen may also be 
Qualitative ilial histomorphometry in children with glucocorticoid- induced 
osteoporosis, with results compared to healthy controls 
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depressed  due  to  adrenal  inactivity  following  chronic  glucocorticoid  therapy (35).  In 
addition,  there is in vitro evidence suggesting that glucocorticoids impair  FSH action, 
thus reducing estrogen secretion (36).
According to Wolff's law, bone grows in response to the magnitude and direction 
of the forces to which it is subjected (37). Glucocorticoids are also well known to cause 
muscle wasting (38). Therefore, glucocorticoid-induced myopathy may contribute to bone 
deficits via the functional muscle-bone unit. 
.
Mechanisms of Glucocorticoid induced bone loss and growth retardation
2.  Growth  Suppression:  Growth  suppression  is  a  long  term  adverse  effect  of 
Glucocorticoid  therapy.  High  dose  glucocorticoid  therapy can  attenuate  physiological 
growth hormone (GH) secretion via an increase in somatostatin tone, and the GH response 
to GH stimulation tests may be reversibly impaired in some cases of steroid exposure (39, 
40). However, glucocorticoid induced growth failure may also be due to direct effects on 
the growth plate. Infusion of glucocorticoids into the growth plate leads to a temporary 
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reduction in the growth rate of that leg and may disrupt the growth plate vasculature (41, 
42).  Glucocorticoid  exposed  chondrocytes  show reduced  proliferation  rates  and  a 
reversible,  prolonged  resting period.  In  vitro  studies  suggest  that  local  somatotrophic 
action of GH and IGF-1 may be affected by a number of different mechanisms,  including 
alterations in the activity of the GH binding protein, down regulation of GH receptor 
expression and binding capacity, and a reduction in local IGF-1 production and activity 
(43-46).
3.  Cushing’s  Syndrome: Cushing’s  syndrome  was  the  term  originally  used  to 
characterize the effects of idiopathic hypercorticism and may be induced by prolonged 
administration  of  glucocorticoids.  The  clinical  features  include  hypertension,  truncal 
obesity,  osteoporosis  and  thinning  of  subcutaneous  tissues.  The  distribution  of  fat  is 
predominantly in the subcutaneous tissues of the upper back and abdomen and produces a 
characteristic ‘buffalo hump’. Skin changes include striae (on the lower abdomen, legs, 
arms and chest), hirsutsm and acne. Hypertension is mild, but may require glucocorticoid 
dose  modification.  Biochemically,  the  illness  is  characterized  by  high  plasma 
glucocorticoid levels and suppression of the hypothalamic pituitary axis. 
4. Immunosuppression
Lymphopenia and neutropenia:  Glucocorticoids act as immunosuppressive agents and 
anti-inflammatory  agents.  They  mask  the  signs  and  symptoms  of  inflammation. 
Glucocorticoids profoundly affect cell – mediated immune reactions, including delayed 
hypersensitivity and allograft rejection. Children receiving high dose glucocorticoid over 
a prolonged period are prone to infections that are associated with defects of delayed 
hypersensitivity like tuberculosis.
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Glucocorticoids  decrease  the  number  of  circulating  lymphocytes,  monocytes, 
basophils  and eosinophils,  but  increase  the  number  of  circulating  neutrophils.  Excess 
glucocorticoids may also cause polycythemia (47).
5. CNS Effects: The glucocorticoid effects on the central nervous system are mediated by 
changes in CNS concentration of plasma glucose and electrolyte balance (47).
a. Psychosis: 
This is more common in idiopathic Cushing’s syndrome than in iatrogenic disease
b. Mood and behavioural disturbances:
In  a  prospective  study  on  children  receiving  high  dose  IV  intermittent 
glucocorticoids,  behavioural  abnormalities  like  altered  mood,  hyperactivity,  sleep 
disturbances and psychosis were noticed.
6. CVS effects: 
a. Hypertension:  Glucocorticoids can cause hypertension by influencing renal sodium 
excretion
b. Dyslipoproteinemia
7. Cataracts and glaucoma
8. Metabolic Effects
a. Impaired carbohydrate tolerance
b. Protein wasting
c. Metabolic acidosis
9. Proximal Myopathy
When considering the use of systemic corticosteroids, one must weigh the risks 
against the benefits of the drug. Though extremely potent and effective against a variety 
of  diseases,  they  are  associated  with  significant  toxicity.  Therefore,  in  using 
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corticosteroids  for  treatment  of  chronic  illnesses,  it  is  imperative  to  monitor  for  the 
adverse effects of the drugs
SSNS  AS  A  MODEL  FOR  STUDYING  EFFECTS  OF  STEROIDS  ON  BONE 
HEALTH
Childhood  Steroid  sensitive  nephrotic  syndrome  provides a  clinical  model  of 
chronic glucocorticoid therapy in the absence of significant underlying disease activity. 
The nephrotic state is clinically quiescent as long as  high-dose glucocorticoid therapy is 
continued.  Unfortunately,  SSNS  relapses  in  the  majority of  children  when  the 
glucocorticoids are  reduced,  which  results in  protracted,  repeated  courses  of 
glucocorticoids. The standard prednisone dose for relapses is 2 mg/kg per day (18) which 
far exceeds  the  5  mg/day that  is  considered  a  risk  factor  for  Glucocorticoid  induced 
osteoporosis in adults(3). Although SSNS relapses are associated with transient increases 
in  cytokines,  these  abnormalities  promptly  resolve with  glucocorticoid  therapy  and 
disease  remission (48).  Therefore, SSNS  is  proposed  as  a  clinical  model  without 
significant systemic inflammatory involvement to examine the effects of glucocorticoids 
on the growing skeleton (49).
RESEARCH INSTRUMENT: DEXA
Dual energy x-ray absorptiometry (DEXA) is a cheap, easily accessible method 
with high precision and accuracy for the measurement of mineral content that employs 
low levels of radiation. DEXA was developed in the late 1980s and was introduced for 
use  in  adults  to  diagnose  and  monitor  the  course  of  osteoporosis,  especially  in  post 
menopausal women.
DEXA is based on the attenuation of two standardized X-ray beams with differing 
energy levels as they pass through different types of body tissue. DEXA makes it possible 
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to differentiate between several body tissues and divide the organism into its content of 
mineral, fatty and lean mass (50).
DEXA  determines  the  mineral  quantity  in  g (bone  mineral  content  -  BMC) 
contained in a given projection of bone. Dividing this mineral content by the bone area 
(BA)  of  the  location  obtains  what  is  conventionally  known as  bone  mineral  density 
(BMD) in g/cm2. 
 A DEXA scan report shows the following measurements:
a) Bone Mineral Content (BMC)
b) Bone Area (BA)
c) Bone Mineral Density (BMD) = BMC / BA
d)  Z score: the difference between the measured BMD and the age-sex matched average
e) T score:  the difference between the measured BMD and the sex matched average 
        young adult standard 
WHO  criteria  for  diagnosing  osteoporosis  in  adults  are  based  on  DEXA  BMD 
measurements (51):
• A T-score within 1 SD (+1 or --1) of the young adult mean indicates normal bone 
density. 
• A T-score of 1 to 2.5 SD below the young adult mean (--1 to -- 2.5 SD) indicates 
low bone mass (osteopenia). 
• A T-score of 2.5 SD or more below the young adult mean (> -- 2.5 SD) indicates 
the presence of osteoporosis
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DEXA USE IN CHILDREN – PROBLEMS
Special considerations are involved in the use of DEXA to assess bone mass in children
1. Comparing the bone mineral density (BMD) of children to the reference data of 
adults (to calculate a T-score) will underestimate the BMD of children, because 
children have less bone mass than fully developed adults. This would lead to an 
over diagnosis of osteopenia for children. Thus, T – scores are meaningless in 
children. To avoid an overestimation of bone mineral deficits, BMD scores are 
commonly compared to reference data for the same gender and age (by calculating 
a Z-score). 
2. There are very few patterns of normative (reference) data available for BMD / 
BMC in children. Horlick et al (52) in a recent study concerned themselves with 
developing  a  model  for  evaluating  bone  mass  by  DEXA  in  children  and 
adolescents,  and concluded that  the variables ethnic origin,  weight,  height  and 
bone area accounted for 89 to 99% of BMD. Furthermore, they pointed out that 
the behavior of BMD was specific to different clinical conditions, suggesting that, 
in addition to all the variables quoted above, the patient's diagnosis must also be 
taken into account when the results of bone densitometry are interpreted. 
3. In addition to age, children pose a unique problem because as time progresses the 
measured  subject  changes  in  shape  and  volume.  An  important  confounding 
variable  in  BMD measurements  is  bone  size.  Because  the  density  obtained  is 
based on area and not volume and because the area does not increase in the same 
proportion as the volume during growth, large bones are overestimated and small 
bones are underestimated in terms of BMD. Infancy and adolescence are periods 
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during which the organism is growing rapidly and, therefore, the size of bones 
vary intensely. Therefore a proportion of the change observed in area-based BMD 
during these periods is not a real increase in mineralization, but, in fact reflects the 
volumetric growth of the skeleton (53). 
DEXA overestimates the BMD of taller subjects and underestimates the BMD of 
smaller  subjects.  Two  recent  studies  by  Wren  et  al  (54),  and  Gafin  &  Baron  (55), 
illustrated  that  failure  to  consider  the  confounding  effect  of  height  results  in  an 
overestimation of bone deficits in children with chronic disease. 
BMC VS BMD AS A MEASURE FOR GROWTH STUDIES
Bone mineral content, not bone mineral density, is the correct bone measure for 
growth studies (56).
Areal Bone Mineral Density (aBMD) obtained by dividing BMC with BA is not 
an accurate measurement of true volumetric bone mineral density, which is mass divided 
by a volume. The confounding effect of differences in bone size is due to the missing 
depth value in the calculation of bone mineral density. It is assumed that BMC and BA 
are directly proportional to one another, such that a 1% change in BA is matched by a 1% 
change  in  BMC.  This  is  rarely  the  case,  and  the  exact  relationship  depends  on  the 
population group, skeletal site, body size, instrumentation, and scanning conditions (57).
There is no mechanical reason why true density should change appreciably with 
growth, and Matkovic et al (58), showed that, in fact, it did not.
BMD is the wrong measurement during growth, because it factors out most of the 
component of bone accumulation that is associated with change in bone size (57, 59). 
What  is  important  in  a  growth  experiment  is  bone  mass  (measured  as  bone  mineral 
content,  BMC).  Despite  DEXA’s problems with estimating volume,  it  is  still  a  fairly 
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accurate measure of bone mineral content.
Although  BMD  plays  a  valuable  role  in  fracture-risk  assessment  and  clinical 
management  in  adults,  it  is  advocated  that  its  use  in  epidemiological  research  be 
discontinued (57).
RADIATION WITH DEXA
Contrary to popular belief, the amount of radiation exposure during a DEXA scan is minimal. The 
radiation dose is approximately 1/10th that of a standard chest X-ray (60).
DEXA AND INTERPRETATION OF BONE HEALTH 
BMD (by DEXA) criteria  for the diagnosis  of osteoporosis  in  children do not 
currently exist. However, DEXA-based parameters (BMC) can be useful to understand 
the patient’s bone health status (61). By applying an algorithm that is based on Frost’s 
mechanostat  theory,  a  primary,  secondary,  or  mixed  bone  defect  can  be  determined 
(62-64).
Algorithm  for  assessment  of  pediatric  osteoporosis  in  the  context  of 
chronic  illness  (proposed  by  Schoenau  et  al.  [65]  for  pQCT,  and 
adapted to DEXA by Crabtree et al  
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FRACTURE RISK ESTIMATION IN CHILDREN
Oral corticosteroids are known to increase the risk of fracture in adults, but their 
effects in children remain uncertain.
The  largest  study  to  evaluate  the  incidence  of  fractures  among  pediatric 
glucocorticoid users was conducted in the UK by Van Staa et al (9). It was a case-control 
study involving over 37,000 children treated with steroids. Results showed that the risk of 
fracture  was  increased  in  children  who  received  four  or  more  courses  of  oral 
corticosteroids for a mean duration of 6.4 days. Fracture risk was also increased among 
children using 30 mg prednisolone or more each day.
Jones et  al.  (65), showed in healthy girls that  a 1 SD reduction in areal BMD 
compared to the age-matched mean was associated with an almost 2-fold
increased risk of forearm fractures.
SKELETAL MINERAL ACQUISITION
The fact that in the prepubertal age group, the rate of skeletal mineral acquisition remains fairly 
equal in both genders has been demonstrated.
In a  study by Rio et  al  (66),  on 471 healthy white  Mediterranean children and adolescents to 
determine  Bone Mineral  Density of  the  Lumbar  Spine  showed  that BMC and BMD values  increased 
progressively from infancy to adulthood and values were similar in both sexes, with the only differences 
related to the earlier onset of puberty in girls. Faulkner, et al also found no significant differences in Total 
Body Bone Mineral Content at any age, between boys and girls 8 - 16 years of age (67).
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CALCIUM AND VITAMIN D IN NEPHROTIC SYNDROME
Hypocalcaemia  is  a  common finding  in  nephrotic  syndrome,  due  primarily  to 
hypoalbuminemia-induced reduction in calcium binding to albumin. A low serum total 
calcium concentration induced by hypoalbuminemia does not affect the physiologically 
important  free  (or  ionized)  calcium  concentration.  A  small  subset  of  patients  with 
hypocalcaemia  out  of  proportion  to  hypoalbuminemia  has  been  reported,  due  to  low 
serum calcitriol concentrations and perhaps increased fecal calcium losses. However, the 
frequency  with  which  true  hypocalcaemia  and  bone  disease  occurs  in  the  nephrotic 
syndrome  is  unclear,  as  many  investigators  have  found  relatively  normal  calcium 
concentrations (68, 69).
Nephrotic syndrome is associated with urinary loss of vitamin D-binding protein 
(VDBP) (70). In serum, calcidiol (D2), the precursor of calcitriol (D3), is primarily bound 
to VDBP and is therefore also excreted in the urine (71,72). The net effect is a reduction 
in serum calcidiol concentrations, while those of calcitriol are normal or reduced (71, 73, 
74). The physiologic consequences of these changes in vitamin D metabolism on calcium 
homeostasis are uncertain. Vitamin D replacement therapy is not routinely recommended 
in patients with the nephrotic syndrome. 
CALCIUM, PHOSPHORUS, VITAMIN D & BONE METABOLISM
Calcium serves two major functions for bone. First, calcium is the bulk cation out of which bone 
mineral is constructed. It must be absorbed in sufficient quantity to build a skeleton during growth and to 
maintain skeletal mass in maturity. Second, calcium serves as an indirect regulator of skeletal remodeling.
Glucocorticoid  administration  is  associated  with  diminished  intestinal  calcium 
absorption and increased renal tubular calcium excretion, resulting in a negative calcium 
balance (75).
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Without vitamin D, only 10 to 15% of dietary calcium and about 60% of phosphorus is absorbed 
(76-78). The interaction of Vit D3 with the vitamin D receptor increases the efficiency of intestinal calcium 
absorption to 30 to 40% and phosphorus absorption to approximately 80% (76 - 79).
In one study, serum levels of 25-hydroxyvitamin D were directly related to BMD in white, black, 
and Mexican-American men and women, with a maximum density achieved when the 25-hydroxyvitamin D 
level reached 40 ng per milliliter or more (80).
Evaluation of the exclusive use of calcium or vitamin D3 (RECORD trial) showed no antifracture 
efficacy for patients (81).
VITAMIN D: REQUIREMENTS AND TREATMENT STRATEGIES
Most experts agree that children and adults require approximately 800 to 1000 IU of Vitamin D3 
per day (76, 77, 80, 82-86)  
A cost-effective method of correcting vitamin D deficiency and maintaining adequate levels is to 
give patients 100,000 IU of vitamin D3 once every 3 months (87). This has been shown to be effective in 
maintaining 25-hydroxyvitamin D levels at 20 ng per milliliter or higher and is also effective in reducing the 
risk of fracture. Alternatively, either 1000 IU of vitamin D3 per day or 3000 IU of vitamin D2 per day is 
effective (76, 84, 85). 
RISK OF VITAMIN D TOXICITY
Doses of more than 50,000 IU per day raise levels of 25-hydroxyvitamin D to more than 150 ng 
per milliliter (374 nmol per liter) and are associated with hypercalcemia and hyperphosphatemia (76, 77). 
Doses of 10,000 IU of vitamin D3 per day for up to 5 months, however, do not cause toxicity (88).
STUDIES ON STEROIDS, BONE HEALTH AND ROLE OF AND CA AND VIT D 
SUPPLEMENTATION
There are studies to suggest that patients with nephrotic syndrome on steroids are indeed at risk of 
low bone density. 
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In a study done on 100 Indian children with Relapsing Idiopathic Nephrotic Syndrome on long 
term steroids using BMD measurements at  lumbar spine by DEXA, Gulati et al (89),  found that these 
children are at risk for low bone mass, especially those administered higher doses of steroids, those with 
longer duration of disease and those with late onset.  
Similar results were found by Basiratnia et al (90), when they measured BMD and 
BMC using DEXA in 37 Iranian children with Steroid Dependent Nephrotic syndrome, 6 
girls  and 31 boys  aged from four  to  21 years,  as  patient  group and 37 age and sex-
matched healthy individuals  as  control  group.  The  percentage  of  BMC and BMD of 
lumbar  spine and femoral  bones of the patients  were significantly lower than control 
group.  BMD at  femoral  and  lumbar  bones  was  inversely  correlated  with  cumulative 
steroid dose. Bone loss was directly proportional to longer duration of the disease and 
higher cumulative dose of steroid. 
A meta-analysis was done by T. P. van Staa et al (91), using information from 66 
papers  on  bone  density  and  23  papers  on  fractures  to  examine  the  effects  of  oral 
corticosteroids on bone mineral  density and risk of  fracture.  Strong correlations were 
found between cumulative dose and loss of bone mineral density and between daily dose 
and risk of fracture. The risk of fracture was found to increase rapidly after the start of 
oral corticosteroid therapy (within 3 to 6 months) and decrease after stopping therapy. 
The risk remained independent of underlying disease, age and gender. They concluded 
that oral corticosteroid treatment using more than 5 mg (of prednisolone or equivalent) 
daily leads to a reduction in BMD and a rapid increase in the risk of fracture during the 
treatment period.
In contrast, in a recent study done by Leonard et al (20), on the effect of long-term 
treatment with glucocorticoids on bone mineral content in 60 children and adolescents 
with relapsing steroid sensitive nephrotic syndrome and 195 control subjects, showed that 
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children  receiving  corticosteroids do not  appear  to  have  deficits  in  the  bone  mineral 
content of the spine.
The effect of prolonged glucocorticoid treatment or intermittent high dose therapy 
on bone health in children has been studied but most of this evidence to date is cross-
sectional in nature. 
There is no clear data available on the effect of short term steroids on bone health. ‘A study on 
skeletal  effects of short term steroids on children with steroid dependent nephrotic syndrome’  done by 
Kenichi Kano et al (92), on 9 Japanese children with steroid-responsive nephrotic syndrome without relapse 
showed that  BMD and biochemical  parameters of mineral  and skeletal  homeostasis returned to normal 
values at 16 weeks after the cessation of prednisolone therapy, thus leading the authors to conclude that the 
skeletal effects of short-term prednisolone therapy were transient. The change in BMD of normal healthy 
children during the period of study (using controls) would have helped establish whether their conclusions 
are indeed true. Further long term follow up of these children is needed to see if short term therapeutic 
doses of corticosteroids lead to acquisitional osteopenia.
In another study , Gulati et al (93), prospectively studied the role of Calcium ( 500 mg/day) and 
Vitamin D ( 200 IU/day ) supplementation on bone health in 88 children with relapsing Nephrotic syndrome 
on steroids by performing DEXA scans at the lumbar spine before and six months after supplementation. 
They found that compared to baseline values, BMD values were significantly better on follow up. However, 
the basic assumption in this study was that  if  there was an increment in the BMD, it  was because of 
supplemental Calcium and Vitamin D. The fact, that children will have an increase in BMD by virtue of 
growth was not accounted for.
Bak  et  al  (94),  conducted  a  randomized  prospective  study  in  Turkey  on  40 
children (mean age of 4.6 +/- 1.8 years) with new onset or relapsing Nephrotic Syndrome 
to determine the effects and prophylactic role of calcium ( 1 g daily ) plus vitamin D ( 400 
IU)  treatment  on  bone  and  mineral  metabolism  in  children  receiving  prednisolone 
treatment. Bone mineral density was significantly decreased in both the treatment and 
non-treatment group but the percentage of bone mineral density decrease was found to be 
32
significantly lower in the treatment group (-2.1%) than in the non-treatment group (- 4%). 
This  led  them  to  conclude  that  steroid  treatment  decreases  bone  mineral  density  in 
children  with  nephrotic  syndrome.  Vitamin  D  plus  calcium  therapy  in  the  above 
mentioned doses reduces but does not completely prevent bone loss, with no additional 
adverse effects. 
A sizable proportion of pediatric  population receives long term treatment with 
steroids for Nephrotic Syndrome. However, there are no clear-cut guidelines as to when 
bone protective strategies must be instituted. This study will help determine short term 
steroid induced bone damage and guide preventive therapy.
METHODOLOGY
STUDY DESIGN AND DURATION
This open randomised controlled interventional prospective study was conducted 
in the Paediatric Nephrology and Endocrine Departments of Christian Medical College 
Hospital, Vellore. The study was conducted for a duration of 3 months from May 2007 to 
July 2008.
SELECTION OF SUBJECTS
Children with new onset nephrotic syndrome were recruited into the study.
INCLUSION CRITERIA
• Patients in the age group of 1 to 13 years.
• Children with first presentation of Nephrotic syndrome.
• (Proteinuria more than 40 mg / m2 /hr or Urine spot protein/creatinine ratio of 
>2).
• No history of prior steroid use.
• No clinical or biochemical evidence of metabolic bone disease.
EXCLUSION CRITERIA
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• Patients with a history of previously known kidney or bone disease
• Patients  with  a  history,  clinical  or  biochemical  evidence  of  metabolic  bone 
disease (e.g. chronic renal failure, liver disease)
• Children not fulfilling the criteria for Nephrotic syndrome (with gross hematuria, 
persistent  hypertension  or  evidence  of renal  disease  other  than  nephrotic 
syndrome) 
• Patients with a serum creatinine > 1.5 mg/dl.
• Patients who were on or had received glucocorticoid therapy.
• Children with onset of puberty - Tanner stage >1
• Patients  on  steroid  sparing  immunosuppression  (Azathioprine,  Mycophenolate 
Mofetil , Cyclophosphamide, Cyclosporine)
• Patients with known or suspected history of hypersensitivity to Prednisolone
STUDY PLAN, PROCEDURE AND FOLLOW UP
All patients with new onset nephrotic syndrome were screened for inclusion in the study
The following tests were done to confirm the diagnosis of nephrotic syndrome:
• Urine Protein Creatinine Ratio       
• Urine Routine examination / Urine Multistix 
• Serum Protein 
• Serum Albumin 
• Serum Cholesterol 
Once diagnosis was established, all those who fulfilled the inclusion criteria and 
who had none of the exclusion criteria were recruited. 
Informed  Consent:  Written  informed  consent  was  taken  from  patients’  parents  / 
guardians prior to enrolment in the study. (See Annexure for Informed consent form)
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Baseline tests were done to rule out metabolic bone disease. These included:
• Serum Calcium
• Serum Phosphorus
• Serum Alkaline Phosphatase
• Serum Creatinine 
Randomization: The children were then randomized into Intervention (Group I) and Non 
Intervention (Group II) groups using block randomisation technique.
Baseline measurements of weight, height and BMI were recorded for all children. 
Baseline Bone Mineral Content (BMC) and Bone Mineral Density (BMD) measurements 
at Lumbar spine were carried out for both groups using DEXA scan. The model of the 
DEXA machine used was DELPHI W – Hologic QDR- 4500 with fan beam.
Both groups received oral Prednisolone in the dose of 60 mg per square metre per 
day (as single daily morning dose) in the first six weeks followed by 40 mg per square 
metre on alternate days (as a single morning dose) in the next six weeks as per the APN 
Regime. The cumulative dose of Prednisolone received by each patient was 3360 mg/m2.
Group I (Intervention), in addition, received the following supplements:
• Oral Vitamin D3( Calcirol granules) 90,000 IU as a single stat dose at the start of 
treatment
• Elemental Calcium 500 mg (as calcium carbonate) as a single morning dose for 12 
weeks
The patients were followed up in Child Health OPD with a minimum of 4- 5 visits for 
each patient
Visit 1: 0 weeks - On admission to the study
Visit 2: 2 weeks - During therapy visit (to look for remission)
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Visit 3: 4 weeks - If not in remission at the end of 2 weeks of treatment 
Visit 4: 6 weeks- During therapy visit (steroid dose reduction)
Visit 5: 12 weeks - End of therapy visit
In addition, patients were also seen as and when required
At each visit a Urine Multi-stix was done to assess for response to steroids. The 
children were also examined for presence of hypertension, infection, adverse effects and 
compliance with medication.
At  the  end  of  12  weeks  both  groups  underwent  DEXA  scan  for  repeat 
measurements  of  BMD  and  BMC  and  Serum  Calcium,  Phosphorus  and  Alkaline 
Phosphatase levels were estimated. 
Concomitant medication: The patients were given concomitant medications whenever it 
was imperative for the benefit of the patient. 
Compliance: The compliance to therapy was evaluated on the basis of actual number of 
doses taken compared to the prescribed doses. This was done by asking the patient to 
bring the medicine along during the follow up visit and cross checking the same with the 
theoretical quantity.
Subject dropout: Those patients who did not complete the study were considered drop 
out cases.
Documentation: All relevant subject information was maintained in the in the proforma 
(Annexure) and outpatient case record 
CALCULATION OF SAMPLE SIZE
In  a  randomised,  controlled  study  on  the  protective  efficacy  of  Calcium and 
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Vitamin D in children on Prednisolone for Nephrotic syndrome by Bak et al (94) , there 
was a decrease of BMD in lumbar spine by 13+/- 4% in control subjects whereas children 
who received Calcium and Vitamin D showed a decrease  of  only 4.6 +/-  2.1%. The 
treatment attributable difference was about 8% and the pooled variance was 10%. Using 
these figures in TRUE EPISTAT, it was calculated that there should be a total of 14 
patients (7 in each arm) to be able to make out an 8% difference in BMD between the 2 
groups with 99% confidence and with a power of 90%.
However, since this study had included children with relapsed nephrotic syndrome 
and since 1) we were studying only new patients diagnosed with nephrotic syndrome 2) 
the age range would also be different in our study, and 3) we would be using BMC as a 
primary diagnostic tool, we felt  that it  would be prudent to study a larger number of 
children.
INTERPRETATION OF RESULTS
There are several ways in which changes in BMD and BMC can be compared in 
studies. Z scores are individual values (of BMD) expressed as standard deviation from 
age sex matched normals.  Such normative data  are  not currently available  for Indian 
children.
When we are studying children of different ages, the baseline BMC and BMD 
values would vary widely so that absolute changes over short periods of time will be 
difficult to compare statistically. If we assume that the baseline BMD & BMC to be 100% 
for that individual and express changes over time , the  percentage changes over the same 
period of time are comparable. This approach , also used by Bak et al (94) , is particularly 
suitable when small numbers are studied. 
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STATISTICAL ANALYSIS OF DATA
Data entry and statistical analysis was done using Microsoft Excel and SPSS for 
Windows Version 16.0. Percentage change in BMC and BMD over basal was determined 
for each subject. The means of this percentage change were calculated in both groups and 
compared using  Paired‘t’ test and Mann Whitney U tests. Inferences on  the protective 
effect of Calcium and Vitamin D supplementation on bone health were drawn using the 
results of these statistical tests.
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RESULTS AND ANALYSIS
CATEGORIES
 1.   PATIENT DISTRIBUTION 
                          Table 1 : PATIENT DISTRIBUTION
CATEGORY No of children (n=34) Percentage
    Intervention               18            52.94% 
    Non Intervention               16            47.06 %
    Total                34            100%
Figure 1 : PATIENT DISTRIBUTION (n = 34)
16, 47%
18, 53%
Intervention
Non Intervention
Table 1 and Figure 1 show patient distribution between the two groups.
34 children were randomized into Group I and II 
52.94% (18/34) belonged to Group I 
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47.06% (16/34) children formed Group II
                              
DEMOGRAPHIC PROFILE
2. AGE DISTRIBUTION  
                               Table 2.1: AGE DISTRIBUTION 
AGE GROUPS No of children (n =34) Percentage
      1 – 2.99 years                   16          47.1 %
      3 – 5.99 years                   11          32.4 %
      6 – 9.99 years                    2          5.9 %
      10 – 13 years                    5             14.7%
             Total                   34           100%
Figure 2.1 : AGE DISTRIBUTION (n = 34)
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Table 2.1 and Figure 2.1 show the overall age distribution of the children included in 
the study
The mean age was 4 .13 years (range 1 year - 12. 4 years)
1- 3 year olds formed the largest group with 47% (16/34) children, followed by 32.4% 
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(11/34) in the 3-6 year age group
2 (5.9 %) children were between 6 – 10 years 
5 (14.7%) children in the 10 -13 age group
         Table 2.2 :  AGE DISTRIBUTION BETWEEN GROUPS
AGE GROUPS             GROUP I             GROUP II
n = 18 Percentage n = 16 Percentage
 1 - 2.99 years        9       50%       7    43.8%
 3 – 5.99 years        5       27.2%       6    37.5%
 6 – 9.99 years        1       5.6%       1    6.2%
 10 – 13 years        3       16.7%       2    12.5%
    Total       18       100.00      16    100.00
                            Table 2.3 :  AGE CHARACTERISTICS 
        GROUP I           GROUP II
 Minimum age          1 year      12 years 5 months 
 Maximum age          1 year 3 months      10 years 7 months
 Mean age          4. 28 years       3. 97 years 
Tables 2.2 & 2.3 and Figure 2.2 show the age distribution in the 2 groups
Both the groups were comparable in age distribution. 
Figure 2.2 : AGE DISTRIBUTION IN GROUPS 
I ( n=18) & II ( n = 16) 
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The mean age in Group I   was 4. 28 years and in Group II was 3.97 years.
3. SEX DISTRIBUTION
                   Figure 3.1: SEX DISTRIBUTION 
Table 3.1 and Figure 3.1 show the overall sex distribution of the Nephrotic children 
recruited in the study
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Male preponderance was noted with a  M: F ratio of 2.4:1.
Table 3.2 :  SEX DISTRIBUTION  BETWEEN GROUPS
GENDER               GROUP I               GROUP II
Frequency Percentage Frequency Percentage
   Male       11      61.1%       13      81.2%
  Female        7      38.9%        3      18.8%
   Total       18       100%       16      100%
   
Figure 3.2: SEX DISTRIBUTION between the 2 groups
Table 3.2 and Figure 3.2 show the gender distribution between the two groups
The male: female ratio in Group I was 1.6:1, while in Group II it was 4.3:1  
4. ETHNIC DISTRIBUTION 
Table 4 : ETHNIC DISTRIBUTION
STATE No of children ( n=34) Percentage
       Tamil Nadu                   24             70.6%
       West Bengal                   5             14.7%
       Jharkhand                   2             5.9%
       Tripura                   2             5.9%
       AndhraPradesh                   1             2.9%
       Total                   34             100%
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Figure 4.1: ETHNIC DISTRIBUTION (n=34) 
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Table 4 and Figures 4.1 and 4.2 (below) represent the Ethnic distribution of the 
subjects included in the study
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Figure 4.2 : ETHNIC DISTRIBUTION ( n = 34)
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Table 4 and Figures 4.1 and 4.2 represent the Ethnic distribution of the subjects 
included in the study
The children recruited came from varied ethnic backgrounds
Majority of the subjects – 70.6% (27/34) belonged to Tamil Nadu. 
5 (14.7%) children were natives of West Bengal 
2 (5.9%) each came from Jharkhand and Tripura  
1 (2.9%) were from Andhra Pradesh. 
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DISEASE CHARACTERISTICS
5. INFECTION AT ONSET 
Table 5.1 : INFECTION AT ONSET
No of children(n=34) Percentage
       Infection                 12            35.3 %
       No Infection                 22            64.7 %
       Total                 34            100 %
Figure 5.1 : INFECTION AT ONSET(n=34)
12, 35%
22, 65%
Infection 
No Infection
Table 5.1 and Figures  5.1 show the proportion of  children who had infection at 
presentation
 35.3% (12/34) children had infections heralding the onset of Nephrotic syndrome 
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                            Table 5.2 : TYPE OF INFECTION 
     Type of Infection No of children ( n=34)         Percentage
             LRI 6 17.6 %
             URI 4 11.7 %
             AGE 1 2.9   %
             Hepatitis A 1 2.9  %
             UTI 1 2.9  %
Figure 5.2 : TYPE OF INFECTION (n = 34)
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Table 5.2 and Figure 5.2 show the types of infections at onset 
The most common was Lower respiratory tract  infection in  50 %( 6/12) followed by 
Upper Respiratory Tract Infections in 11.7% (4/12).
Acute Gastroenteritis, Hepatitis A, and Urinary tract Infections affected 1 child each
6. HYPERTENSION AT ONSET
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Table 6 : HYPERTENSION AT ONSET
 No of children (n=34)        Percentage
 Hypertension              7            20.6%
 No Hypertension             27            79.4%
 Total ( n = 34 )             34            100 %
Figure 6 : HYPERTENSION AT ONSET (n = 34)
7, 21%
27, 79%
Hypertension
No hypertension
Table 6 and Figure 6 represent the incidence of hypertension at disease onset in 
children with Nephrotic Syndrome
21% (7/34) patients were hypertensive at presentation
7. REMISSION
Urine analysis was done to look for proteinuria. This was done at every visit to 
evaluate  response  to  steroid  therapy.  Remission  was  concluded based  on  the  clinical 
features of resolution of edema and Urine Multistix being normal. The remission rates of 
the subjects were assessed at 2, 4, 6 & 12 weeks. 
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Table 7 : REMISSION RATE
REMISSION 2 weeks 4 weeks 6 weeks 12 weeks
Proteinuria - 28
(82.4 %)
30
(88.2%)
33
(97.1%)
31
(91.2%)
Proteinuria + 6
(17.6 %)
4
(11.8%)
1
(2.9%)
3
(8.8%)
Total (n = 34) 34 34 34 34
Figure 7 : REMISSION (n = 34)
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Table 7 and Figure 7 demonstrate the remission characteristics of all the children 
included in this study
82.4% (28/34) children went into remission by 2 weeks, 
88.2% (30/34) by 4 weeks and
97.1% (33/34) by 6 weeks.
91.2 %( 31/34) children remained in remission at the end of 12 weeks
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2 children who were in remission at 6 weeks, relapsed on tapering steroid dose. 
1 went into remission on restarting full dose steroids; the second remained non responsive 
(Renal biopsy showed MesPGN)
8. RELAPSE 
Table 8.1 : RELAPSE
No of children ( n=34) Percentage
Relapse 13 38.6 %
No relapse 21 61.8 %
Total  (n = 34) 34 100 %
Table 8.1 : RELAPSE ( n = 34)
13, 38%
21, 62%
Relapse
No Relapse
Table 8.1 and Figure 8.1 show the incidence of relapse
Of the total number of children recruited in the study 38.6% (13/ 34) relapsed
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                   Table 8.2 : RELAPSE ON/ OFF TREATMENT  
 No of children (n=13)         Percentage 
Relapse on steroids                  2               15.4 %
Relapse off steroids                 11               84.6 %
          Total                  13               100 %
         
Figure 8.2 : RELAPSE ON / OFF 
STEROIDS ( n = 13)
2, 15%
11, 85%
On steroids 
Off steroids
          Table 8.2 Figure 8.2 show proportion of relapse while on steroids
15.4% (2/13) children relapsed while on treatment with steroids. 
Majority (85%-11/13) relapsed after stopping steroids
Mean time to relapse was 11.5 weeks (range 7 - 22 weeks)
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Table 8.3 : CAUSE OF RELAPSE
Cause of relapse           No of Patients   Percentage of Patients
Spontaneous 7 53.8 %
Due to Infection 6 46.2 %
Total  (n = 13) 13 100 %
Figure 8.3 : CAUSE OF RELAPSE ( n = 13)
7, 54%
6, 46%
Spontaneous
Due to Infection
Table 8.3 and Figure 8.3 show causes of relapse
46.2% (6/13) children had a relapse following an infection
Viral fever and URI were the most common infections precipitating relapse
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9. SIDE EFFECTS OF STEROIDS 
                                Table 9 : SIDE EFFECTS OF STEROIDS
    SIDE EFFECT            At 6 weeks         At 12 weeks
Frequency Percentage Frequency Percent
age
Cushingoid        28      82.4%       34      100%
Hypertrichosis        5      14.7%       21      61.8
%
Gastritis        27      79.4%       25      73.5
%
Striae        0      0          2       5.9%
Infection        7      20.6%       3       8.8%
Behaviour change        2      5.9%       3       8.8%
Hypertension        0      0       0       0
Acne        0      0       0       0
Purpura        0      0       0       0
Cataract        0      0       0       0
Glucosuria        0      0       0       0
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Table 15 and Figure 15 illustrate the side effects of steroids experienced by the 
subjects participating in the study
Side effects of steroids experienced by the children were recorded at 6 and 12 weeks.
Cushingoid  habitus  (100%),  gastritis  (79.4%),  hypertrichosis  (67.8%)  and  infection 
(20.6%) were the most commonly noted side effects. 
8.8 %( 3/34) children had behavior changes and 5.9% (2/34) had striae. 
A decrease in the incidence of gastritis was noted from 79.4% (27/34) at  6 weeks to 
73.5% (25/34) at 12 weeks.
Marked  increase  in  hypertrichosis  seen  at  12  weeks  (67.8%)  compared  to  6  weeks 
(14.7%)
20.6% (7/34) children had infections at 6 weeks and 
8.8% (3/34) at 12 weeks. 
Figure 9 : SIDE EFFECTS OF STEROIDS ( n = 34)
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10. ADDITIONAL MEDICATIONS 
Table 10.1 : ADDITIONAL MEDICATIONS
Additional medications used No of children (n=34) Percentage
Yes 26 76.4%
No 8 23.6%
Total 34 100%
Table 10.2  :  MEDICATIONS
    MEDICATION No of children (n = 34) Percentage
    Spironolactone 22 64.7 %
    Frusemide 17 50 %
    Antibiotics 14 41.2 %
    Nifedipine 5 14.7%
    Others (Atenolol, 
Metalozone, ATT )
3 8.8 %
Figure 10 : ADDITIONAL MEDICATIONS  (n =34) 
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Tables 10.1 & 10.2 and Figure 10 represent the additional medications used during 
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the duration of the study
76.4% (26/34) children required additional medications 
The commonest were diuretics for control of edema 
64.7% (22/34) were given Spironolactone 
50% (17/34) required Frusemide
1 child received Metalozone
41.2% (14/34) children received antibiotics to treat infections
 
Blood Pressure control was achieved with Nifedipine in 5 (14.7%) children and Atenolol 
in 1 (2.9%) child
1 child was given Anti Tuberculous Therapy (ATT) because of asymptomatic Mantoux 
positivity.
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BODY CHARACTERISTICS 
11. WEIGHT
              Table 11.1: WEIGHT CHARACTERISTICS - GROUP I
Mean Weight  (Kg) Minimum Weight (Kg) Maximum Weight 
( Kg)
Baseline 16.16 7.3 41.7
At 12 
weeks
16.03 8.0 37.6
Table 11.2:WEIGHT CHARACTERISTICS - GROUP II
Mean Weight ( Kg) Minimum Weight (Kg) Maximum Weight 
( Kg)
Baseline 14.91 8.2 32.7
At 12 
weeks
15.68 9.8 27.4
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Figure 11.1: MEAN WEIGHT (kg)
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Tables 11.1 &11.2 and Figure 11.1 shows the weight characteristics in Groups I & II
Table 11.3 : MEAN WEIGHT CHANGE
      PARAMETERS GROUP I GROUP II
 Mean Weight Change (%) =
 ∑(Final Wt – Initial Wt  )     x 
100
           (Initial Weight)
+ 1.2477% + 7.7362%
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Figure 11.2:MEAN WEIGHT CHANGE(%)
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Table 11.3 and Figure 11.2 illustrate the mean % weight change in the 2 groups
There was a net weight gain in both groups.
An average 1.25 % increase in weight in Group I and 7.7 % weight gain in Group II over 
a 12 week period.
The  difference  in  the  mean  (%)  change  in  weight  between  the  2  groups  was  not 
statistically significant (p value = 0. 222, 95% CI = - 17.09 to +4.12 on Paired ‘t’ test).
12. HEIGHT 
Table 12.1 : HEIGHT CHARACTERISTICS – GROUP I
     Mean Height
(cm)
Minimum
Height (cm)
Maximum
Height (cm)
   Baseline 95.561 70 148
   At 12 weeks 97.200 70 149
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Table 12.2 : HEIGHT CHARACTERISTICS – GROUP II
      Mean Height
(cm)
Minimum
Height (cm)
Maximum
Height (cm)
    Baseline 93.481 74 127.5
    At 12 weeks 95.438 75 129
Figure 12.1 : MEAN HEIGHT(cm)
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Tables 12.1 & 12.2 and Figure 12.1 shows the height characteristics of Groups I &II
                           Table 12. 3 :  HEIGHT CHANGE 
         GROUP             Mean Height Change (%) =
 ∑     (Final Height - Initial Height  )     x 100
                 (Initial Height)
         Intervention 1.8820 %
        Non Intervention 2.1050 %
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Figure 12.2 : MEAN HEIGHT CHANGE ( %)
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Tables 12.3 and Figure12.2 represent the mean % height change in the 2 groups
At 12 weeks, children in both the groups stood taller.
1.88 % gain in height in Group 1 and 2.11 % in Group II.
No statistically significant difference was found in the mean % change in height in the 2 
groups (z = - 0.518, p = 0.605 on Mann Whitney U test)
13. BMI 
TABLE 13 : BMI CHARACTERISTICS
      PARAMETERS         GROUP I           GROUP II
   Initial  Final    Initial    Final
Minimum BMI (kg/m2) 14.5 13.6 13.8 12.9
Maximum BMI (kg/m2) 20.2 19.5 21.0 26.9
Mean  BMI (kg/m2) 16.567 16.178 16.569 16.988
Mean BMI change (%) =
61
 ∑   (Final BMI – Initial BMI)
             ( Initial BMI)
- 1.783% + 3.826%
Figure 13.1: MEAN BMI (kg/m2)
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Table 13 and Figure 13.1 represent the BMI characteristics in Groups I & II
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Figure 13.2 : BMI CHANGE (%)
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Table 13 and Figure 13.2 represent the mean % BMI change in Groups I & II
Mean 1.783 % decrease in BMI in Group I over 12 weeks.
In contrast, 3.826% increase in BMI in Group II.
No statistically significant difference in the 2 Groups 
(z = -1. 242, p = 0.214 on Mann Whitney U test).
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14. SERUM CALCIUM
                                Table 14 :  CHANGE IN CALCIUM
      PARAMETERS    INTERVENTION NON INTERVENTION 
   Initial  Final    Initial    Final
Minimum Ca (mg/dL)      8.8   8.5     8.8      8.6
Maximum Ca (mg/dL)     10.6   10.0     10.5     10.8
Mean  Ca (mg/dL)     9.550   9.422     9.653     9.520
Mean %Ca change  =
 ∑   (Final Ca – Initial Ca)
             ( Initial Ca)
      
            - 1.1595 %         - 0.6928%
 Figure 14 : CALCIUM CHANGE (%)
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Table 14 and Figure 14 show the % change in Serum Calcium levels in 
Groups I & II
Serum Calcium (corrected for the corresponding Serum albumin) was maintained 
in the normal physiological range in all children in both groups both at baseline and at 12 
weeks.
Drop  in  Serum  Calcium  in  both  Groups  when  calculated  as  %  change  over 
baseline: 1.16% decrease in Group I (received Calcium & Vitamin D supplements), 0.7% 
decrease in Group II. No statistically significant difference between the 2 groups (z = 
-0.057,  p = 0.955 on Mann Whitney test) 
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DEXA
In order to evaluate the changes occurring in bone with short term steroid use and 
the  prophylactic  role  of  Calcium and  Vitamin  D  in  preventing  the  deleterious  bone 
changes, serial DEXA scans were performed and both Bone Mineral Content (BMC) and 
Bone Mineral Density (BMD) were estimated. A baseline DEXA Scan was done prior to 
starting therapy with steroids, followed by repeat testing at end of treatment at 12 weeks.  
The 12 week estimations were compared to the baseline and percentage change 
over baseline was calculated.  Thus,  each patient was his/  her own control .The mean 
percentage change in BMC and BMD was computed for the both the groups. Paired T – 
test and Mann Whitney tests were used for determining statistically significant difference 
between the two groups.
 1
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5. BONE MINERAL DENSITY (BMD in g/cm2)
Table 15.1: BMD DATA IN GROUP I 
                         
Table 15.2: BMD DATA IN GROUP II
Tables 15.1 and 15.2 represent the BMD data for each of the subjects in the 
Intervention and Non Intervention groups
Figure 15.1: Distribution of BMD variables in Intervention group
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Figure 15.2: Distribution of BMD variables in the Non Intervention group 
Table 15.3 :  BMD CHANGE
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PARAMETERS INTERVENTION (I)
NON 
INTERVENTION(NI)
Initial Final Initial Final
Minimum BMD (g/cm2) 0.285 0.276 0.285 0.289
Maximum BMD (g/cm2) 0.702 0.671 0.497 0.499
Mean  BMD (g/cm2) 0.410 0.418 0.400 0.406
Mean % BMD change  =
 ∑ (Final BMD – Initial BMD) x 100
             ( Initial BMD)
+ 2.7736 % + 1.6338 %
MANN WHITNEY U TEST: MEAN (%) BMD CHANGE IN GROUPS I & II
Ranks
CATEGORY N Mean Rank Sum of Ranks
 Mean (%) change
           in BMD
Intervention 18 18.56 334.00
Non intervention 16 16.31 261.00
Total 34
Test Statisticsb
Mann-Whitney U 125.000
Wilcoxon W 261.000
Z - 0.656
Asymp. Sig. (2-tailed) 0.512
Exact Sig. [2*(1-tailed Sig.)] 0.528a
a – not corrected for ties
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Figure 15.3: BMD CHANGE (%)
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Tables 15.3 and Figure 15.3 show the mean % change in BMD over baseline in 
Groups I & II over 12 weeks.
There was an increase in BMD in both groups
 
In Group I (Intervention group) the BMD increased by 2.77% 
In Group II, the rise was by 1.63%
The  percent  change  in  BMD was  not  normally  distributed  in  the  two  groups 
(Figure 15.1 & 15.2). Therefore Mann -Whitney U test (a non parametric test) was used 
for comparing the 2 groups.  This showed no difference between the 2 groups in this 
parameter (z = -0.656, p = 0.512)
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16. BONE MINERAL CONTENT (BMC in g) 
Table 16.1: BMC DATA IN GROUP I
Table 16.2: BMC DATA IN GROUP II
Tables 16.1 and 16.2 represent the BMC data for each of the subjects in the 
Intervention and Non Intervention groups.
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Figure 16.1: Distribution of BMD variables in Intervention group
Figure 16.2: Distribution of BMC variables in the NI group  
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Table 16.3 : BMC  CHARACTERISTICS IN I & NI GROUPS
PARAMETERS INTERVENTION NON INTERVENTION
Initial Final Initial Final
Minimum BMC (g) 4.22 5.08 5.55 5.40
Maximum BMC (g) 25.53 24.72 16.63 13.97
Mean  BMC (g) 9.798 10.516 9.712 8.603
Mean % BMD change  =
 ∑ (Final BMC – Initial BMC)  x 100
             ( Initial BMC)
+ 11.2565 % - 10.4689%
MANN WHITNEY U TEST ON MEAN (%) BMC CHANGE IN GROUPS I& II
         Ranks CATEGORY N Mean Rank Sum of Ranks
Mean Change in 
BMC (%) Intervention 18 24.22 436.00
Non intervention 16 9.94 159.00
Total 34
Test Statisticsb
Mean Change in BMC (%)
Mann-Whitney U 23.000
Wilcoxon W 159.000
Z -4.175
Asymp. Sig. (2-tailed) 0.000
Exact Sig. [2*(1-tailed Sig.)] 0.000a
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Figure 16.3: MEAN BMC CHANGE(%)
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Table 16.3 and Figure 16.3 show the BMC characteristics and mean % change in 
BMC over baseline in Groups I & II and the distribution of values
11.3% increase in the BMC of subjects in Group I (Intervention group) over a 12 
73
week period
As opposed to that,  in Group II, over the same period, the BMC decreased by 
10.4689 %.
It is apparent that the values for percentage change over basal are not normally 
distributed in the two groups (Figures 16.1 & 16.2). Therefore a Mann Whitney U test 
was performed and this showed a statistically significant percentage increase in BMC in 
children who received Calcium and Vitamin D compared to children who did not receive 
this intervention ( z = -4.175 , p <0.001).
The net  intervention  attributable  difference  in  Bone Mineral  Content  in  the  2 
groups was 21.6%.
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DISCUSSION
This open randomized controlled interventional prospective study to evaluate the 
role of prophylactic Calcium and Vitamin D in preventing short  term steroid induced 
bone  loss  in  children  with  Nephrotic  syndrome  was  conducted   in  the  Paediatric 
Nephrology subunit of the Child Health Department and the Endocrinology Department 
of the Christian Medical College Hospital, Vellore. 
Of the 46 children recruited, 4 children dropped out during the course of treatment 
and did not complete the study. 34 children had completed their 3 month follow up and 
were considered for the final analysis. The remaining 8 patients were still on treatment 
and have thus not been included in the analysis.
Of  the  34  children  analyzed,  18  (53%)  were  randomized  into  Group  I 
(Intervention  group)  and 16  (47%) into  Group II  (Non Intervention  group)  (Table  1, 
Figure 1).
The age of the children recruited ranged from 1 year to 12 year 5 months. The 
mean age was 4.13 years (Table 2.1 and Figure 2.1). According to literature, children 
develop Nephrotic Syndrome while younger than 18 years. Approximately 75% are under 
the age of 6 years with peak incidence between 2-3 years (95).The age distribution of the 
children in our study was also predominantly 1-6 years. The largest group, 16/34 (47%), 
was formed by 1- 3 year  olds,  followed by 11 (32.4%) in the 3-6 year  age group. 2 
(14.7%) children were between 6 – 10 years and 5 (14.7%) children in the 10 -13 age 
group). The mean age in Group I and II was 4.28 years and 3.97 years respectively. Both 
the groups were comparable with respect to age distribution. (Tables 2.2 & 2.3, Figure 
2.2)
Of the 34 children, 70.6% (24/34) were boys and 29.4% (10/34) were girls (Table 
75
3.1, Figure 3.1).The male: female ratio was 2.4:1. In the Cochrane Database review done 
by Hodson et al (17) on children with Nephrotic syndrome, the male to female ratio was 
1.2:0.9.  An unpublished study done on Nephrotic children in the department of Child 
Health in CMC, Vellore in 2006 reported a male: female ratio of 1.5:1.In our study also a 
male preponderance was observed.  
The children recruited came from different ethnic backgrounds (Table 4, Figures 
4.1 & 4.2). Majority of the subjects 70.6% (27/34) belonged to the state of Tamil Nadu. 
14.7% (5/34) were natives of West Bengal, 5.9% (2/34) each hailed from Jharkhand and 
Tripura and 2.9% (1/34) were from Andhra Pradesh. 
Minor infections are known to precipitate Nephrotic syndrome in children (1). In 
our study, we found that 35.3% (12/34) children had infections heralding the onset of 
Nephrotic syndrome (Table 5.1, Figure 5.1). Of these, the most common were Lower 
respiratory  tract  infections  (17.6%),  followed  by  Upper  Respiratory  Tract  Infections 
(11.7%). Acute Gastroenteritis, Hepatitis A, and Urinary tract Infections affected 1 child 
each (2.9%) (Table 5.2, Figure 5.2). None of the infections were life threatening and most 
could be treated on an outpatient basis. 26% (9/34) required hospitalization and antibiotic 
therapy. 
ISKDC studies (12) demonstrate that approximately 30% of patients with Minimal 
Change Nephrotic Syndrome have both systolic and diastolic pressures above the 90th 
percentile for age. According to them, when values above the 98th percentile were used to 
denote an abnormality, then approximately 20% had systolic pressures that were elevated 
and about 13% of the diastolic pressures were aberrant.  Our study showed similar results. 
20.6% (7/34) patients had hypertension at onset of the Nephrotic syndrome (Table 6 & 
Figure 6). However, hypertension was transient and antihypertensive medications could 
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be withdrawn by 2 weeks. 
Urine analysis (using Multistix) was done to evaluate response to steroid therapy. 
Remission  was  concluded  based  on  clinical  features  of  resolution  of  edema  and 
proteinuria (i.e. urine multistix showing nil or trace proteinuria). The Remission rate was 
assessed at 2, 4, 6 and 12 weeks in our study (Table 7 & Figure 7).82.4% (28/34) children 
went into remission by 2 weeks,  88.2% (30/34) by 4 weeks and 97.1% (33/34) by 6 
weeks. At 12 weeks, 31 (91.2%) patients remained in remission.
These figures were consistent with earlier studies. Most of the literature suggests 
that 80 to 90% of children will respond to therapy by 2 weeks (1). In a report from the 
International  Society  of  Kidney  Disease  in  Children  (ISKDC),  it  was  found  that 
approximately 90 percent of patients who will respond to steroids do so within four weeks 
after starting steroids, with the remaining 10 percent going into remission after two to 
four  more  weeks  of  a  daily  steroid  therapy  (12). This  implies  that  it  is  probably 
worthwhile  waiting  for  6  weeks  to  achieve  remission  in  children  with  nephrotic 
syndrome, thereby avoiding renal biopsy which is invasive and can have complications. 
In our study, 2 children underwent renal biopsy because of late onset of nephrotic 
syndrome and were found to have Mesangioproliferative Glomerulonephritis. Of the two, 
1 was steroid responsive and the other required slow tapering of steroids.
At the time of analysis, 38.6% (13/34) of the children relapsed during or after 
treatment  (Table  8.1  &  Figure  8.1).  2  (15.4%)  children  who  relapsed  had  achieved 
remission by 6 weeks on full dose of steroids, but had proteinuria on lowering the steroid 
dose (Table & Figure 8.2). The time to relapse after stopping steroids ranged between 7 
and  22  weeks,  average  being  11.5  weeks.  In  46.2% (6/13)  children,  the  relapse  was 
precipitated by an infection (Table 8.3 & Figure 8.3). Viral fever and URI were the most 
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common infections precipitating relapse. The duration of the study was not designed for 
long  term  follow  up,  and  therefore,  the  number  of  children  who  relapsed  does  not 
represent the true incidence.
In his report on the prognostic significance of the early course of minimal changes 
nephrotic syndrome, Tarshish et al (15) stated that 30 percent of treated patients will not 
have a relapse and therefore will be cured after the initial course of therapy. Ten to 20 
percent will relapse several months after steroid treatment is discontinued, but will have 
less than four steroid-responsive episodes before permanent remission occurs. A relapse 
rate of 38.6% was found in our study.
During the course of the study, children were assessed for the presence of side 
effects of steroids. Adverse effects of steroids are represented in Table 9 & Figure 9. 
Cushingoid  habitus  (100%),  gastritis  (79.4%),  hypertrichosis  (67.8%)  and  infection 
(20.6%) were the most commonly noted side effects. 8.8% children each had behavior 
changes and 5.9% striae. Elevated blood pressures, acne, purpura, cataract and glucosuria 
were not found in any of the subjects during the 12 weeks of steroid treatment.
The higher incidence of gastritis and infections at 6 weeks compared to 12 weeks 
may reflect their dose dependent nature. Marked increase in hypertrichosis seen at 12 
weeks compared to 6 weeks implies it appears after prolonged steroid use. 
Steroid therapy mainly had minor side effects in our study. Infection was the most 
serious side effect observed. 20.6% (7/34) children had infections at 6 weeks of treatment, 
and 8.8% (3/34) at 12 weeks. It is known that children with Nephrotic syndrome have 
lowered ability to fight infections and that steroids suppress the immune system. Higher 
doses cause greater suppression. This indicates the need for an active search of any focus 
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of infection and prompt treatment of the same including hospitalization (if required) in 
these children.
76.4%  (26/34)  children  required  additional  medications  (Tables  10.1  &  10.2, 
Figure 10).The commonest were diuretics for control of edema - 64.7% (22/34) were 
given  Spironolactone  and  50%  (17/34)  required  Frusemide.  41.2%  (14/34)  children 
received  antibiotics  to  treat  infections.  Blood  Pressure  control  was  achieved  with 
Nifedipine in 5 (14.7%) children and Atenolol in 1 (2.9%) child. 1 child was given Anti 
Tuberculous Therapy (ATT) because of asymptomatic Mantoux positivity.
At each outpatient visit the weight was recorded. The percentage change in the 
weight over 12 weeks duration compared to the initial weight was calculated for each 
child. The mean of this percentage change in weight in Group I and II were computed. 
Both  groups  showed  weight  gain,  1.25%  in  Group  I  and  7.7%  in  Group  II  (Table 
11.3&Figure  11.2).  The  difference  in  weight  gain  was  not  found  to  be  statistically 
significant. The exact significance of this is not known as both groups had received the 
same dose of steroids.
Growth  suppression  is  a  known adverse  effect  of  Glucocorticoid  therapy  and 
occurs in children on long term therapy. Emma et al (96) found that children with steroid-
responsive Nephrotic syndrome are at risk of permanent growth retardation secondary to 
prolonged  courses  of  steroid  treatment.  Whether  Calcium  and  Vitamin  D  co- 
administration with steroids can prevent this stunting is therefore an important question.
The height of all children was thus recorded at each visit and the change analyzed. 
The percentage change in height in 12 weeks (over baseline height) was computed for 
each subject and the mean was calculated for both the groups. Children in both groups 
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stood taller at the end of 12 weeks. There was an average height gain of 1.88% in Group I 
and 2.11% in Group II (Table 12.3&Figure 12.2). No statistically significant difference 
was found between the 2 groups. The increase in height was probably a reflection of the 
normal physiological growth of children. It is also pertinent to mention here that a 12 
week period is too short to demonstrate stunting or the beneficial effect of Calcium and 
Vitamin D on the same in children on steroids.
Percentage change in BMI over baseline was calculated in a fashion similar to the 
weight  and height change (Table 13,  Figure 13.2).  Group I  patients  showed a fall  of 
1.78% in 12 weeks. In contrast,  in Group II patients BMI increased by 3.82%. When 
subjected to analysis, no statistically significant difference in the % change in BMI was 
found in the two groups 
Hypocalcaemia  is  a  common finding  in  nephrotic  syndrome,  due  primarily  to 
hypoalbuminemia-induced reduction in calcium binding to albumin. A low serum total 
calcium concentration induced by hypoalbuminemia does not affect the physiologically 
important  free  (or  ionized)  calcium  concentration.  A  small  subset  of  patients  with 
hypocalcaemia  out  of  proportion  to  hypoalbuminemia  has  been  reported,  due  to  low 
serum calcitriol concentrations and perhaps increased fecal calcium losses. However, the 
frequency  with  which  true  hypocalcaemia  and  bone  disease  occurs  in  the  nephrotic 
syndrome  is  unclear,  as  many  investigators  have  found  relatively  normal  calcium 
concentrations (68, 69).
A published study from Switzerland conducted by Lippuner et al (97) on renal 
transplant  children  who  received  steroids  demonstrated  a  less  than  normal  level  of 
Calcium among his subjects. In our study, Serum Calcium measurements were performed 
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at baseline and after 12 weeks. Serum Calcium (corrected for the corresponding Serum 
albumin) was maintained in the normal physiological range in all 34 (100%) children 
during both measurements. The percentage change in serum calcium levels over baseline 
values  was  determined  for  each  subject  and  the  mean  in  Group  I  (which  received 
supplemental Calcium & Vitamin D) and Group II were compared. Both groups showed a 
drop in Calcium levels (1.1% in the Group I and 0.7% in Group II (Table 14, Figure 14), 
however the difference was not statistically significant. Serum Calcium estimation may 
be  reserved  for  patients  with  symptoms  of  hypocalcaemia  or  a  low corrected  serum 
calcium concentration.
There  is  increasing  awareness  that  children  are  not  exempt  from  developing 
osteoporosis. Threats to bone health that are operative during the pediatric years may be 
particularly costly long-term, since growth and development of the skeletal system play a 
critical role in determining bone strength and stability in later years (10).
Glucocorticoids are  used  in  myriad  pediatric  diseases  including  nephrotic 
syndrome, asthma, juvenile rheumatoid arthritis,  inflammatory bowel disease, systemic 
lupus erythematosus, and organ transplantation. It is estimated that 10% of children may 
require  some form of glucocorticoids  at  some point in  their  childhood (3).  Prolonged 
steroid  use  is  known  to  cause  osteoporosis.  Osteopenia  in  children  receiving  a 
prednisolone dose of less than 0.16 mg/kg/day has been reported (7, 8).
Childhood  Steroid  sensitive  nephrotic  syndrome  provides a  clinical  model  of 
chronic glucocorticoids therapy in the absence of significant underlying disease activity. 
The  course  of  SSNS is  characterized  by relapses  which result in  protracted,  repeated 
courses  of  glucocorticoids. The  standard prednisone  dose for  new  onset  disease  and 
relapses is 2 mg/kg per day (18) which far exceeds the 5 mg/day that is considered a risk 
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factor for glucocorticoid induced osteoporosis in adults (3).
The  largest  study  to  evaluate  the  incidence  of  fractures  among  pediatric 
glucocorticoid users was conducted in the UK by Van Staa et al (9). It was a case-control 
study involving over 37,000 children treated with steroids. Results showed that the risk of 
fracture  was  increased  in  children  who  received  four  or  more  courses  of  oral 
corticosteroids for a mean duration of 6.4 days. Fracture risk was also increased among 
children using 30 mg prednisolone or more each day.
The deleterious effects of steroids on bone are maximum during the first 6 months 
of  treatment.  Studies  have  shown that  the greatest  reduction in  bone mineral  content 
(BMC) and BMD among children with leukemia occurred during the first 6–8 months of 
chemotherapy (23-26). Hence, new onset nephrotic syndrome was chosen for determining 
the effect of steroids on bone over a 3 month period.
Glucocorticoid (GC) toxicity appears to have a predilection for trabecular bone 
(29). This is supported by the propensity of GCs to affect the spine. Hence, spine would 
be the target area for assessing steroid induced bone changes. 
Dual energy x-ray absorptiometry (DEXA) is a cheap, easily accessible method 
with high precision and accuracy for the measurement of mineral content that employs 
low levels of radiation. DEXA determines the mineral quantity in grams (Bone Mineral 
Content-  BMC) contained  in  a  given  projection  of  bone  (BA).  Dividing  this  mineral 
content by the bone area of the location obtains Bone Mineral Density (BMD). Hence, 
BMC and BMD measurements at lumbar spine using the DEXA scan can be used for the 
diagnosis and follow-up of steroid induced bone disease. In children acquisition of bone 
mass is due to a) increase in length and width of bone and b) an increase in bone mineral 
density. If one uses only bone mineral density, it may not truly reflect changes in bone 
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mass. 
Nephrotic syndrome is associated with urinary loss of vitamin D-binding protein 
(VDBP) (70). In serum, calcidiol (25- hydroxy Vitamin D), the precursor of calcitriol (1, 
25- dihydroxy Vitamin D), is primarily bound to VDBP and is therefore also excreted in 
the urine (71, 72). The net effect is a reduction in serum calcidiol concentrations, while 
those of calcitriol are normal or reduced (71, 73, and 74). The physiologic consequences 
of  these changes  in  vitamin D metabolism on calcium homeostasis  are  uncertain  and 
Vitamin D replacement therapy is not routinely recommended in patients with nephrotic 
syndrome. 
There is data to suggest that Vitamin D plus Calcium is superior to no therapy or Calcium alone in 
the  management  of corticosteroid-induced  osteoporosis  (80,  81).  In  our  study,  we  used  Vitamin  D to 
counter steroid induced bone changes. The dose used (1000 IU/day) was much higher than the dose used 
for routine supplementation (200 - 400 IU /day) but was in the dose range used for preventing steroid 
induced bone disease. The safety and efficacy of administering such high dose Vitamin D has been proved 
(88).
Although the detrimental effect of steroid treatment on children’s bones  
has been well known for years, no recommendations have been suggested for the 
prevention of diminished BMD and BMC in children with nephrotic syndrome. 
There are no clear cut guidelines as to when bone protective strategies must be  
instituted. This prospective randomized study was thus undertaken to determine  
the need of prophylactic calcium and Vitamin D supplementation in children on  
short  term  steroids.  Using  Bone  Mineral  Density  (BMD)  and  Bone  Mineral  
Content (BMC) as tools, those receiving supplementation were compared with  
those not receiving it. 
BMD interpretation is difficult in children. 
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Comparing the BMD of children to the reference data of adults (T-score) will lead 
to an over diagnosis of osteopenia for children. BMD scores must therefore be compared 
to reference data for the same age (Z-score). There are very few patterns of normative 
(reference) data available for BMD in children. 
BMD is obtained based on area and not volume and because the area does not 
increase  in  the  same  proportion  as  the  volume  during  growth,  large  bones  are 
overestimated and small bones are underestimated in terms of BMD. The confounding 
effect of differences in bone size is due to the missing depth value in the calculation of 
BMD. It is assumed that BMC and BA are directly proportional to one another, such that 
a 1% change in BA is matched by a 1% change in BMC, but this is not true.
BMD is  therefore is  not  the  preferred  measurement  during growth,  because  it 
factors out most of the component of bone accumulation that is associated with change in 
bone size (57, 59). What is important in assessing skeletal mineral acquisition is bone 
mineral content (BMC).
Except for a study done by Leonard et al (20), there are no other studies using 
BMC as a tool to assess bone loss. He studied the effect of long-term glucocorticoids on 
BMC in 60 children and adolescents with relapsing steroid sensitive nephrotic syndrome 
and 195 normal control subjects. He showed that children receiving corticosteroids do not 
appear to have deficits in the BMC of the spine. It was not possible to include normal 
controls  in  our  study due  to  ethical  considerations  of  subjecting  healthy  children  to 
DEXA scans.
In  a  study  done  on  100  Indian  children  with  Relapsing  Idiopathic  Nephrotic 
Syndrome on long term steroids using BMD measurements at lumbar spine by DEXA, 
Gulati et al (89) found that these children are at risk for low bone mass, especially those 
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administered higher doses of steroids, those with longer duration of disease and those 
with late onset.  
Similar results were found by Basiratnia et al (90) when they measured BMD and 
BMC using DEXA in 37 Iranian children with Steroid Dependent Nephrotic syndrome. In 
their study, 6 girls and 31 boys with ages ranging from four to 21 years formed the patient 
group and 37 age and sex-matched healthy individuals were taken as control group. The 
percentage of BMC and BMD of lumbar spine and femoral bones of the patients were 
significantly lower than control group. BMD at femoral and lumbar bones was inversely 
correlated with cumulative steroid dose. Bone loss was directly proportional to longer 
duration of the disease and higher cumulative dose of steroid.
The effect of prolonged glucocorticoid treatment or intermittent high dose therapy 
on bone health in children has been studied but most of this evidence to date is cross-
sectional in nature. 
There is little data available on the effect of short term steroids on bone health. ‘A 
study  on  skeletal  effects  of  short  term  steroids  on  children  with  steroid  dependent 
nephrotic syndrome’ done by Kenichi Kano et al (92) on 9 Japanese children with steroid-
responsive  nephrotic  syndrome  without  relapse  showed  that  BMD  and  biochemical 
parameters of mineral and skeletal homeostasis returned to normal values at 16 weeks 
after the cessation of prednisolone therapy, thus leading the authors to conclude that the 
skeletal effects of short-term prednisolone therapy were transient. The change in BMD of 
normal healthy children during the period of study (using controls) would have helped 
establish whether their conclusions are indeed true. Their sample size was probably too 
small to make valid conclusions. Further long term follow up of these children is needed 
to see if short term therapeutic doses of corticosteroids lead to acquisitional osteopenia.
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In another study , Gulati et al (93) prospectively studied the role of Calcium ( 500 
mg/day) and Vitamin D ( 200 IU/day ) supplementation on bone health in 88 children 
with relapsing Nephrotic syndrome on steroids by performing DEXA scans at the lumbar 
spine before and six months after supplementation. They found that compared to baseline 
values,  BMD  values  were  significantly  better  on  follow  up.  However,  the  basic 
assumption in this study was that if there was an increment in the BMD, it was because of 
supplemental Calcium and Vitamin D. The fact, that children will have an increase in 
BMD by virtue of growth was not accounted for. This problem could have been avoided 
by the use of age matched controls, whose BMD change over the same period could have 
been assessed and used as a comparison.
Bak et al (94) conducted a randomized prospective study in Turkey on 40 children 
(mean  age  of  4.6  ±  1.8  years)  with  new onset  or  relapsing  Nephrotic  Syndrome  to 
determine the effects and prophylactic role of calcium ( 1 g daily ) plus vitamin D ( 400 
IU  )  treatment  on  bone  and  mineral  metabolism  in  children  receiving  prednisolone 
treatment.  BMD was  significantly  decreased  in  both  the  treatment  and  non-treatment 
group but the percentage of BMD decrease was found to be significantly lower in the 
treatment  group  (-  4.6  %)  than  in  the  non-treatment  group  (-13%)  ,  showing  a  net 
treatment attributable difference of 8.4 % in the BMD. Here, it  would be pertinent to 
point out that > 50% subjects included were children with relapsing nephrotic syndrome 
who would have been previously treated with steroids and therefore may have had pre 
existing bone mineral deficits. This may have minimized the steroid induced changes as 
in  relapsing  nephrotic  syndrome children may have started off  with  lower  BMD and 
BMC values to begin with. 
Measurement of changes in skeletal mineral acquisition during childhood should take into 
consideration the following facts  
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a) Bones increase in length 
b) Bones increase in girth 
c) There is increased mineral deposition in unit volume of bone.
During steroid therapy, all three components of skeletal mineral acquisition are affected 
due to 
a) Inhibition of growth hormone secretion and action
b) Increased resorptive osteoclastic activity
c) Reduced osteoblastic activity
Therefore  it  has  been  suggested  that  height,  skeletal  X  ray  and  DEXA 
measurements should be used in conjunction to derive normative values.
If one were to use DEXA measurements, BMC is better than BMD because at the 
lumbar spine level BMC would take into account girth of the bone and the amount of 
mineral deposited in unit area.
There  is  a  further  problem  in  assessing  changes  with  time  in  children  with 
nephrotic syndrome. This is because children of different ages will be studied and the rate 
of mineral acquisition varies depending on age. We therefore studied only pre-pubertal 
patients in the age 1 to 12.4 years as the rate of mineral acquisition is linear in during this 
period.
In order to overcome the effects of inclusion of children of different ages, some 
workers use age and sex matched control values and express individual values as standard 
deviation scores called ‘Z’ scores. However, these have to be derived by study of large 
number  of  children  in  each  age  group  belonging  to  the  same  ethnic  group.  Such 
normative values are not available for Indian children. 
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Some others use percentage change over basal values so that the change in BMD 
or BMC over time reflects the effect of disease or intervention. If one chooses children 
between 1-12 years of age when skeletal mineral acquisition is linear, this approach is 
quite useful. However, this cannot be used in pubertal children where the rate of bone 
growth and mineral acquisition differs between the two sexes and the changes are non 
linear.
In our study, it was noted that BMD increased only marginally, both in absolute 
value and in  percentage change calculated over  baseline in both groups.  (Table  15.3, 
Figure 15). In Group I (Intervention group) the BMD increased by 2.77%. In Group II, 
the rise was by 1.63%. The difference in % change in BMD in the 2 groups was not 
statistically significant 
Our  analysis  showed  that  percentage  change  in  BMC  was  starkly  different 
between the 2 groups (Table 16.3, Figure 16). There was a 11.3% increase in the BMC 
(over baseline) of subjects in Group I (Intervention group) over a 12 week period. As 
opposed to that, in Group II, over the same period, the BMC decreased by 10.4689 %. 
The difference in the average (%) change in BMC between the Group I and Group II  was 
found to be highly significant on a Mann Whitney U test ( z = - 4.175 , p < 0.001 ). 
In our study, bone mineral density expressed as percent change over basal did not 
show a  significant  difference  between  nephrotic  children  who  received  Calcium and 
Vitamin D and those who did not in contrast to observations by Bak et al and Gulati et al. 
However, BMC increment in the treated group was significantly higher than in the control 
group indicating a positive 21.6% treatment effect in those treated.
This occurred in the absence of any significant differences in height increment. 
This implies that the observed change in BMC in the treatment group is attributable to 
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increases  in  vertebral  girth  rather  than  to  vertebral  height  or  bone  mineral  density 
changes.
The fact that Bone Mineral Content of growing children decreased after 12 weeks 
of steroid therapy in the control group in our study just reaffirms the detrimental effects 
of  steroids  on the  bone.  BMD was  not  a  sensitive  indicator  of  steroid  induced bone 
changes in our study. This confirms the superiority of BMC measurements over BMD in 
determining changes in bone health in growing children. 
Studies by Gulati et al, Kano et al and Bak et al all used BMD as a tool for bone 
health evaluation. The pitfalls of using BMD as an evaluation tool in growing children 
have been pointed out. This may be a major drawback in their studies. The use of BMC 
could have validated the observations made in their studies. 
In our study, children receiving Calcium and Vitamin D supplements showed a 
marked increase in BMC (11.3%) in contrast to controls that showed a 10.4 % fall in the 
same. This proves the beneficial effect of Calcium & Vitamin D supplementation on bone 
mass in children on steroid therapy. The exact quantitation of this beneficial effect would 
have been possible by comparison with healthy age, sex matched controls.
The net treatment attributable difference in Bone Mineral Content in the 2 groups 
was 21.6%. Hence, it would be logical to conclude that prophylactic Calcium (500 mg 
elemental calcium per day) and Vitamin D (1000 IU / day) supplementation in children 
with 1st episode of nephrotic syndrome helps rectify defects in bone mineral acquisition 
caused by steroids.
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SUMMARY
• 46 children were recruited into the study and followed up over 12 weeks. 34 children 
had  completed  the  study at  the  time of  analysis,  4  were dropouts  and 8 are  still 
undergoing treatment.
• The children were randomized into 2 groups: 
o Group 1: 18 children received steroids and Calcium and Vitamin D
o Group 2:  16 children received steroids only
• Children in the age group of 1 year to 12.42 years were recruited into the study over a 
period of 15 months. The mean age was 4.13 years. Group 1 and Group 2 had similar 
age distribution.
• There were 24 boys and 10 girls. The male: female ratio was 2.4: 1.
• Majority of the children belonged to Tamil Nadu (24), followed by West Bengal (5), 
Jharkhand (2) , Tripura (2) and Andhra Pradesh (1).
• In  35%  (12/34)  children,  infections  triggered  onset,  majority  being  LRI  (6/12), 
followed by URI (4/12). 1 each had Acute Gastroenteritis, Hepatitis A and Urinary 
Tract Infection.
• 20.6% (7/34) children had hypertension at onset.
• By 2 weeks, 82.4% (28/34) children were in remission, 88.2% (30/34) by 4 weeks and 
97% (33/34) by 6 weeks.
• By 12weeks, 91.2% (31/34) remained in remission.
• 38.6% (13/34) patients relapsed, 85% after stopping steroids and 15% while tapering 
steroids. In 46% (6/13), relapse was triggered by an infection. Viral fever and URI 
were the most common infections precipitating relapse.
• Cushingoid features (100%), gastritis (79.4%), hypertrichosis (67.8%) and infections 
(20.6%)  were  the  most  commonly  observed  side  effects  of  steroids.  8.8%  had 
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behavior changes and 5.9% had striae.
• Higher incidence of gastritis and infections at 6 weeks compared to 12 weeks may 
reflect dose dependent nature of these side effects.
• 76.4%  (26/34)  received  additional  medications  in  the  form  of  diuretics  – 
spironolactone (64.7%) and frusemide (50%), antibiotics (41.2%), antihypertensives – 
nifedipine (14.7%), atenolol (2.9%) and ATT (2.9%).
• Change in Weight , Height and BMI  and Serum Calcium over 12 weeks calculated 
over baseline showed no statistically significant difference between the 2 groups 
• A net weight gain of 1.24 % in Group I and 7.7% in Group II was observed.
• Group I & II showed 1.88 % and 2.11 % increase in height respectively. 
• BMI decreased by 1.78 % in Group I; in Group II it increased by 3.826% 
• Serum Calcium (corrected for the corresponding Serum albumin) was maintained in 
the normal physiological range in all children. 
• Serum Calcium dropped by 1.16% in Group I and 0.69 % in Group II. Despite the 
drop, Serum calcium values remained within the normal range at 12 weeks.
• There was a small gain in BMD in both groups 2.77% in Group I and 1.63% in Group 
II. The difference between the 2 Groups was not significant. 
• Children receiving Calcium and Vitamin D supplements showed a marked increase in 
BMC (11.3%) in contrast to controls who showed a 10.4 % fall in the same. The 
difference in the 2 groups was highly significant ( z = - 4.175 , p < 0.001)
• The net intervention (Ca & Vitamin D administration) attributable difference in Bone 
Mineral Content in the 2 groups was 21.6%.
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CONCLUSIONS
1. Bone Mineral Content of growing children decreased by 10% after 12 weeks of 
steroid therapy in the control group confirming the detrimental  effects  of high 
dose short term steroids on the bone.
2. BMD increased only marginally both in absolute value as well as a percentage 
change over baseline in both treatment and control groups. BMD measurements 
failed  to  detect  steroid  induced bone changes  in  our  study.  This  confirms  the 
superiority of BMC rather than BMD in determining changes in bone health in 
growing children.
3. Children  receiving  Calcium and Vitamin  D supplements  showed  a  significant 
improvement  (11.3%) in  the BMC in contrast  to  controls  who showed a 10% 
decrease in the same. 
4. Prophylactic  Calcium and  Vitamin  D  supplementation  is  useful  in  preventing 
steroid  induced  bone  changes  as  demonstrated  by  a  net  treatment  attributable 
change in BMC of 21.6%.  
5. Short  term steroid  therapy  had  minor  adverse  effects  -  Cushingoid  features  , 
Gastritis and Hypertrichosis  being the most common. Infections were the only 
serious adverse effect noted.
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RECOMMENDATIONS
1. Supplementation with Calcium (500 mg /day of elemental Calcium) and 
2. Vitamin  D (1000  IU /day)  during  steroid  therapy in  children  with  new onset 
nephrotic syndrome.
3. Use  of  Bone  Mineral  Content  (BMC)  as  a  diagnostic  tool  in  growth  studies 
assessing bone health
4. Further long term follow up of these children with nephrotic syndrome is needed 
to determine if short term therapeutic doses of corticosteroids lead to acquisitional 
osteopenia in later years. These studies will assess the need to continue Calcium 
and Vitamin D supplementation after stopping steroids.
5. Studies of bone mineral acquisition in normal healthy children so that normative 
data can be obtained . This will be useful for deriving ‘Z’ scores for interpreting 
DEXA studies in children.
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LIMITATIONS
1. BMC and BMD measurements  could not  be performed on age,  sex and body 
surface area matched healthy children due to ethical reasons. If performed, they 
could have helped us determine the extent of steroid induced bone loss and the 
degree of protection provided by supplementation with Calcium and Vitamin D.
2. The study could not be double blinded as it was not possible to obtain a suitable 
placebo.
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ANNEXURE - I
DATA COLLECTION PROFORMA
GENERAL INFORMATION
          
o Name :                                      
o Hospital No:                                     
o Date of birth :                                        
o Sex  : M  /  F
o Category : Intervention / Non Intervention
o Address:
o Phone no :
ANTHROPOMETRY 
Baseline 12 weeks
   Weight
    Height
    BMI *
    BSA**
*    BMI = Body Mass Index
** BSA = Body Surface Area
MONITORING OF NEPHROTIC STATUS        
                 
Baseline 2 weeks 4 weeks 6 weeks 12 weeks
Urine Protein / Creatinine 
Ratio
Serum Cholesterol
Total Protein
Serum Albumin
Edema
Urine Multistix
             Proteinuria
       
INVESTIGATIONS
Baseline 12  weeks
Serum Calcium
Serum Phosphate
Serum Alkaline 
Phosphatase
Serum Creatinine     ----
DEXA
Lumbar spine BMC
BMD
Additional Medications used 
Hospital admissions
OTHER COMPLICATIONS OF STEROIDS 
       Complications Baseline 6 weeks 12 weeks
      Hypertension
      Hirsutism
      Acne
      Striae
      Purpura
      Cushingoid
      Behavioural 
change
      Cataract / 
Glaucoma
      Infection
      Type of infection
      Glucosuria
      Gastritis
TREATMENT DETAILS
         
• Date of starting treatment:
• Date of completing treatment:
• Duration of treatment > 12 weeks: Yes / No
• Total duration of treatment :
• Cumulative dose of steroids :
• Relapse : Yes / No
o Time of relapse :  
o On treatment: Yes / No
o If  No, duration since stopping treatment ….........weeks
o Cause of relapse : spontaneous / infection
Type of infection :
ANNEXURE - II
INFORMED CONSENT DOCUMENT
The  Child  Health  Department  of  Christian  Medical  College  Hospital,  Vellore 
would like you to read this informed consent document (If you cannot read it, it would be 
read out to you). It involves your child’s illness – nephrotic syndrome, the investigations 
involved, its treatment and follow up.
 
Corticosteroids  like  Prednisolone  are  the  recommended first  line  treatment  for 
nephrotic syndrome. The usual duration of treatment  is  12 weeks.  The drug used for 
treatment  does  cause  thinning  of  bones.  There  are  no  standard  recommendations  for 
preventing such bone loss.
In a previous study on similar children, Calcium and Vitamin D were shown to 
have a protective effect when steroids had to be used for several months. Therefore, it 
would be important to know if supplements of Calcium and Vitamin D would have a 
protective effect on bones when a short course of steroids is used for this disorder.
The way to assess changes in bone mineral density is by doing a DEXA scan. This 
will be done two times during the study. The radiation exposure when this scan is done is 
about 1/10th of the radiation exposure when a Chest X ray is performed. Serum Calcium, 
Phosphorus and Alkaline Phosphatase will also be measured 2 times during the study. We 
will undertake to investigate your child free of cost to you. You are requested to agree to 
the tests recommended by the doctors. You are free to refuse. Should you refuse, it will in 
no way affect the medical care provided for your child here.
   
This is a randomised clinical trial. Therefore, 50% of children in the study will not 
get Calcium or Vitamin D. There are no known adverse effects to these doses of Calcium 
and  Vitamin  D.  This  study  will  help  us  to  determine  whether  routine  Calcium and 
Vitamin D supplementation is needed in children with this disorder.
Should you have any further questions, you can contact 
Dr Surabhi Choudhary, Department of Child Health, Christian Medical College Hospital, 
Vellore – 632004,  Phone No : 09443288151
A copy of this information paper is for you to keep. If  you are willing please sign the 
attached consent form. 
Patient’s name : 
Hospital No:
                                          CONSENT FORM 
Title of the Project:  Short term steroids and BMD
I confirm that I have read and understand the information sheet for the  above study 
and have had the opportunity to ask questions
1. I understand that my child’s participation is voluntary and that I am free to withdraw 
him / her at any time , without giving any reason , without his/her medical care or 
legal rights being affected.
2. I understand that sections of any of the medical notes (pertaining to my child taking 
part in this research) may be looked at by responsible individuals. I give permission 
for these individuals to have access to my child’s records.
3. I agree to have my child take part in the above study
---------------------------------     --------------------------------------      -------------
Name of the parent /                              Signature                                Date
legal guardian
---------------------------------      --------------------------------------     -------------
Name of the Witness                             Signature                                 Date
---------------------------------      ---------------------------------------     ------------
Name of the Researcher                         Signature                                Date
सूचना  पत
िििियन मेििकल कॉलेज वेललोर का बाल िवभाग आपसे इस सूचना  (जो  आपके बचचे की 
बीमारी नेफोििक िसंडोम की जांच, िचिकतसा और पनुः जांच के बारे मे है ) को पढने का अनुरोध 
करता है.अगर आप पढ नहीं सकते तो सूचना आपको पढ कर सुनायी जाएगी.
नेफोििक िसंडोम की िचिकतसा मे पमुख रप से पेििनसोलोन जैसे सिेरोइडस का पयोग िकया 
जाता है.िचिकतसा की सामानय अविध 12 हफते होती है. इस दवाई के पयोग से हिडियाँ पतली हो 
जाती है.  हिडियो की इस कित को रोकने के िलए कोई मानक अनुशंसा नहीं है.  
पूव व मे इस तरह के बचचो पर िकये गए एक अधययन मे पाया गया है िक कई महीनो तक 
सिेरोइडस का सेवन करनेवाले बचचो को कैिलशयम और िविािमन िी देने से हडिी पर सिेरोइडस 
के कुपभावो से उनकी रका होती है.  इसिलए ये जानना महतवपूण व होगा िक इस रोग से गसत 
बचचो को अलप अविध के सिेरोइडस के साथ यिद कैिलशयम और िविािमन िी को पूरक के रप 
मे िदया जाए तो कया इसका उनकी हिडियो पर रकातमक पभाव होगा ?
हडिी मे इससे होनेवाले पिरवतनव ो के मूलयांकन के िलए िेकसा सकैन िकया जायेगा. इस परीका मे 
होनेवाला रेििएशन सीने के एकस रे मे होनेवाले रेििएशन का दशांश है.  अधययन के दौरान िेकसा 
दो बार होगा.  अधययन की अविध मे खनू मे कैिलशयम,  फोसफोरस और अलकलाइन  फोसफेिेस 
की जांच  भी दो बार की जायेगी. ये सारी जांच मुफत मे की जायेगी.
हमे िििियन मेििकल कॉलेज से ये जांच करने की अनुमित दी गयी है. आपसे आगह है िक आप 
जांच करने के िलए अपनी सहमित दे दे.आप सहमित देने से मना करने के िलए सवतंत है. अगर 
आप सहमित नहीं भी देते है तो भी आपके बचचे का सही इलाज होगा.
ये अधययन एक  रैनिमआइसि  कलीिनकल टायल  है. इसिलए इस अधययन मे शािमल 50 % 
बचचो को कैिलशयम और िविािमन िी नहीं िदया जायेगा.  कैिलशयम और िविािमन िी की इन 
खुराको के कोई जात कुपभाव नहीं है .इस अधययन से हमे ये िनिशिचत करने  मे मदद होगी 
िक इस रोग से गसत बचचो को सामानय अनुपूरक के रप मे कैिलशयम और िविािमन िी की 
आवशयकता है या नहीं .
अगर आपके इस बारे मे कुछ और सवाल है तो आप िननमिलिखत से समपकव  करे -
िॉ सुरिभ चौधरी , बाल िवभाग , सी एम ्सी एच वेललोर , फोन न : 09443288151
इस सूचना पत की एक पित आपके पास रहेगी. अगर आप सवेचछा से अपने बचचे को इस 
अधययन मे शािमल करने की सहमित देते है तो सहमित पत पर अपने हसताकर कर दे .
बचचे का नाम  :
हॉिसपिल नंबर  :
                                                          सहमित पत  
शोध का शीषवक  : अलप अविध सिेरोइडस बी म िी शोध
1.  मै इसकी पुिि करता हँू िक मैने उपरोक अधययन से संबंिधत सूचना पत को पढा और समझा 
है तथा मुझे उससे जुिे पश पूछने का मौका भी िमला है .
2.  मै समझता हँू िक इस अधययन मे मेरे बचचे / बचची की सहभािगता ऐिचछक है  तथा यह िक 
मै िकसी भी समय िबना कोई कारण बताये उसे वापस लेने के िलए सवतंत हँू , िजसका उसके 
सवासथय की देखभाल एवं कानूनी अिधकारो पर कोई पभाव नहीं पड़ेगा .
3.  मै समझता हँू िक मेरे बचचे/बचची के इलाज समबनधी नोटस का कोई अंश (जो इस शोध 
काय व से पासंिगक है  ) िजममेवार वयिकयो दारा देखा जा सकता है . मै उन वयिकयो के िलए 
अपने बचचे के रेकॉडस व को देखने की अनुमित देता हँू  .
 
4.  मै अपने बचचे के उपरोक अधययन मे शािमल होने से सहमत हँू  .                                  
-----------------------------------------       ---------------------------------------        -----------------
       माता /िपता/अिभभावक का नाम           हसताकर 
िदनांक
-----------------------------------------      -------------------------------------------      -----------------
       साकी  का नाम                                     हसताकर 
िदनांक
      ----------------------------------------      --------------------------------------------      ----------------
       शोधकता व   का नाम                         हसताकर 
िदनांक







